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Synthesis and Antimicrobial Activities of S,S’-Heterosubstituted Disulfides 
Praveen Ramaraju 
 
ABSTRACT 
 
Antibiotic resistance is a particularly critical health concern and has increased 
dramatically over the past two decades. For over a decade the Turos laboratory has 
been designing small molecules to target pathogenic microbes such as Staphylococcus 
aureus and the resistant variants like methicillin-resistant Staphylococcus aureus 
(MRSA). Previously, N-thiolated β-lactams, N-thiolated 2-oxazolidinones and 
aromatic disulfides that were synthesized in Dr. Turos’ lab have shown strong activity 
against these bacteria. The present work describes the synthesis and antimicrobial 
activities of a related structural class called S,S’-heterosubstituted disulfides. For 
ages, sulfur (elemental) has been used as an antibacterial for controlling infestation 
and bacterial diseases. This is the starting point of this thesis. Chapter 1 discusses the 
various sulfur-containing antibiotic compounds and the importance of sulfur 
compounds to exhibit inhibitory activity against disease-causing pathogens. Also in 
this introductory chapter, the different sulfur functionalities and their respective 
modes of action were presented. The synthesis and the antimicrobial activities of the 
title compounds are described in chapter 2. S,S’-heterosubstituted disulfides were 
found to possess inhibitory activities against Staphylococcus aureus, methicillin-
xiii 
 
resistant Staphylococcus aureus (MRSA), Francisella tulerensis and the fungi 
Candida albicans. From the bacterial viability assay and the trypan staining assay, 
these compounds were found to be bacteriostatic and fungistatic, and these 
structurally-simple disulfides may serve as new leads to the development of effective 
antibacterials for drug-resistant staph infections.  
X
S
S
X
X = O, N, S
R
R
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CHAPTER ONE 
 
ORGANOSULFUR ANTIINFECTIVES 
 
 
1.1 Introduction 
The use of organosulfur compounds to control infectious diseases has its roots dating 
back to early times, when ancient Egyptians recognized the potent medicinal effects of 
naturally occurring organosulfur substances from leeks. In 1824 powered sulfur was 
shown to treat peach mildew
1
 and over the centuries, it has successfully been applied as a 
fungicide to protect a wide variety of plants against fungal infestation
1
. Although the 
mode of antifungal action of elemental sulfur is not fully defined, there is no doubt of its 
dependency on the reaction of sulfur with a biological target. 
1.2 Biological Targets of Organosulfur Drugs 
Due to the exposure of living organisms to various infection-causing pathogens, over 
time they developed defenses against harmful biological oxidants and disinfectants. The 
thiol-disulfide equilibrium in cells plays a vital role, creating a natural defense system 
that helps rid the cell of potentially damaging chemicals and metabolites that cause 
oxidative degradation. Nature protects various bacteria from oxidative stress by 
maintaining high thiol:disulfide ratios in the cytosol, typically 19:1 or higher. Disruption 
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of this redox system can alter many vital cellular activities such as regulation of protein 
activity, regeneration of enzymatic cofactors and reductases like ribonucleotide 
reductase, and a host of other biological processes where an antioxidant is required in the 
cell
2
.  
1.2.1 Glutathione-based Systems 
For many years, glutathione (1) (γ-L-glutamyl-L-cysteinylglycine), a tripeptide, serves as 
the active component of the most common thiol/disulfide redox system in many cells. 
Glutathione is produced biologically via the glutaredoxin enzymatic pathway (Fig 1.1). 
Biosynthesis of GSH occurs in all cell types via two reactions catalyzed by γ-glutamyl 
cysteine synthetase (γ-GCS) and GSH synthetase (GS). γ-GCS catalyzes the formation of 
a peptide bond between the γ-carboxyl group of glutamate and the α-amino group of 
cysteine. Glutathione synthetase forms the peptide bond between the α-carboxyl of 
cysteine in γ-glutamyl cysteine and the α-amino group of glycine.
3
 The equilibrium 
between free thiol and disulfide, at stasis, is typically maintained at a cytoplasmic thiol 
concentration of around 90%. Cells with high intracellular glutathione levels are 
generally less susceptible to damage by organosulfur drugs. Serving a primary role as an 
antioxidant, glutathione is extremely effective in scavenging reactive free radicals, 
electrophiles and other destructive oxidants in the cytoplasm. Glutathione can react 
directly with various drugs to deactivate them before they are able to cause any damage, 
while also serving to reactivate enzymes that have been inhibited as mixed disulfides 
formed between a drug and enzyme. In response to this protective mechanism afforded 
by glutathione, nature has cleverly designed prodrug molecules such as the endiyne 
trisulfides and anthracyclines, which can interact directly with glutathione as a way to be 
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biochemically activated within the target cell. Inhibition of glutathione’s antioxidant 
abilities can be induced by formation of mixed glutathione drug disulfides
4
. Reduction of 
glutathione disulfide (GSSG) and mixed disulfides to GSH is catalyzed by glutathione 
reductase, which seems to play a crucial role in evolutionary adaptation of organisms to 
atmospheric oxygen. Glutathione reductase is widespread among bacteria, fungi, plants, 
protozoa, and animals. All glutathione reductases isolated from different sources are 
highly homologous, showing high evolutionary conservativeness of this protein.
3
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Figure (1.1) Biosynthetic pathway of Glutathione 
 
1.2.2 Coenzyme A-based Systems 
For many years, glutathione was assumed to be present in all cells. However, it is not 
entirely ubiquitous. Some bacteria are totally devoid of glutathione, but in its place have 
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some other thiol/disulfide based redox system. S. aureus does not utilize glutathione at 
all, but rather produces millimolar levels of the nucleosidic thiol, coenzyme A (2) 
(CoA)
5
. At stasis, the bacterium maintains a ratio of thiol:disulfide of about 95:5, via 
coenzyme A disulfide reductase (CoADR) (Fig 1.2). This redox system is very selective 
in its ability to reduce CoA disulfide. Mixed disulfides formed between CoA and 
glutathione, or other thiophilic agents, are typically unable to be reduced by CoADR
5,6
. 
The fate of these mixed disulfides is not clearly known. Therefore, anti-infective 
compounds that can form CoADR resistant mixed disulfides with CoA can offer an 
effective mode of inhibition interfering with the redox buffer, providing an opportunity to 
enhance the susceptibility of the bacterial cell to oxidative damage. Indeed, glutathione is 
an inhibitor of the redox cycle of CoA, as it forms mixed CoA-glutathione disulfides that 
cannot be reductively cleaved, and is detrimental to the growth of this bacterium.  
 
Antioxidant Activity
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Figure (1.2) Coenzyme A redox system 
 
1.2.3 Thioredoxin-based Systems 
Another very important group of native cellular thiols / disulfides are the thioredoxins 
(trx’s) and a related subfamily, the disulfide bridge forming enzymes (DBE’s), which 
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span through the bacterial membrane connecting the cytoplasm with the periplasm (Fig 
1.3). The characteristic Cys-X-X-Cys motif in the structures of the trx’s is highly 
conserved in many bacteria. These dithiols undergo reversible oxidation and can quickly 
react with non-native thiols or disulfides. Before a drug even passes through the 
membrane of a bacterium however, a subfamily of thioredoxins, the DBE’s, could 
intervene. Formation of mixed disulfides between the trx’s and an organothio compound 
can potentially inhibit enzymatic reduction by disulfide reductases and thus can perturb 
proper cellular function. 
HS SH
S S
Reduction/ Oxidation of
 Periplasmic Substrates
HS
HS
thioredoxin
Normal Electron Flow
DBE
Periplasm
Cytoplasm
 
Figure (1.3) Regular thiol and disulfide interactions with Thioredoxins 
 
DBE’s, for the most part, inhabit the cytoplasmic membrane with exposed (Cys-X-X-
Cys) functionalities on both the cytoplasmic and periplasmic surfaces. DBE’s are 
involved in electron transport across the membrane and serve as a signaling mechanism, 
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communicating the oxidation state of the cytoplasmic trx’s with the oxidation state on the 
periplasmic side. Disulfide formation involving trx motifs on either side of the membrane 
can cause disruption of the DBE’s electron transport abilities, affecting a host of cellular 
processes such as respiration and cytochrome syntheses. Although there is evidence that 
DBE repair enzymes exist
7,8
, their effectiveness and versatility against non-native thiols 
or sulfides has not been reported. 
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S S
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Drug
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Figure (1.4) Thiol and disulfide bearing drug interactions with Thioredoxins 
 
So, these extraordinarily reactive, native groups represent significant potential as drug 
targets.  
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1.2.4 Mycothiol-based Systems 
The redox buffer in case of Actinomycetes is that of mycothiol (3), which acts as the 
primary antioxidant
9
. First discovered in a species of Streptomyces, and then identified in 
Mycobacterium bovis, mycothiol has since been found to be prevalent only amongst 
actinomycetes and is produced in high levels by mycobacteria. Mycothiol undergoes 
metal-catalyzed autoxidation at a slower rate than GSH
10
 and is maintained in the 
reduced state by mycothiol disulfide reductase.
11
 
O
O
OH
OH
N
H
OH
SH
NH
O
HO
HO
HO
OH
OH
O
3  
Figure (1.5) Mycothiol 
1.2.5 Bacillithiol-based Systems 
Bacillithiol (4) is the α-anomeric glycoside of L-cysteinyl-D-glucosamine with L-malic 
acid and most probably functions as an antioxidant. Bacillithiol, like the structurally 
similar mycothiol, may serve as a substitute for glutathione. Bacillithiol is used as a 
buffer system in Bacillus species, Staphylococcus aureus and Deinococcus 
radiodurans.
12
 
 
Figure (1.6) Bacillithiol  
O
O
OH
OH
N
H
OH
O OH
OH
O
SH
H2N
O
4
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1.2.6 Other Cellular Targets of Organosulfur Antiinfectives 
Another potential intracellular thiol target is adenosine triphosphate synthase (ATPase). 
ATPase is responsible for regeneration of the energy source of cells, adenosine 
triphosphate (ATP) (5), from adenosine diphosphate and inorganic phosphate (Fig 1.7). 
ATPase, which sits on the membrane of mitochondria, contains a reactive, free thiol that 
is vital to activity. Inhibition of ATPase, therefore, can be achieved by formation of a 
mixed disulfide. 
N
N
NH2
N
NO
OHHO
OP
OH
O
O
P
OH
HO
O
P
OH
O
ON
N
NH2
N
N
O
OHHO
OP
OH
O
O
P
OH
HO
O
P
OH
O
O
ATP synthase
Inorganic phosphate
Adenosine diphosphate Adenosine triphospahte (5)  
Figure (1.7) Synthesis of Adenosine Triphosphate (5) 
 
1.3 Classes of Biologically-Active Organosulfur Compounds 
Organic compounds that contain sulfur exhibit an extraordinary range of chemical 
structures and reactivities. Many of these have biological activity. In the simplest case, 
the presence of one or more sulfur atoms in a biologically active molecule may not 
actually give the compound its biological effects, but rather may be a non-participant in a 
side chain residue or an innocuous constituency of the molecular framework. Important 
examples of this are the bicyclic β-lactams, including penicillins (6), cephalosporins (7), 
and penems (8), and the sulfa drugs (9). Most of the β-lactam drugs act by inhibiting the 
transpeptidation reaction responsible for the synthesis of peptidoglycan, a key component 
of the bacterial cell wall that provides rigidity.
13, 14
 Sulfa drugs are known to inhibit the 
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synthesis of folic acid in bacteria by competing with para-aminobenzoic acid. The anti-
infective activity of these drugs does not appear to be directly related to a sulfur-centered 
event nor its presence in the molecule. 
 
N
S
O
ROCN
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N
S
O
OH
COOH
R
N
S
HN
R
S
O
O
NH
R'
X
COOH
O
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6 7
8
9
H H
 
Figure (1.8) Bicyclic β-Lactams and Sulfa Drugs. 
 
In case of thiosugars, the sulfur atom exerts a more definitive, yet subtle, effect on its 
biological activity. These sulfur analogs of the natural sugars and nucleosides act as 
inhibitors of glycosidases and reverse transcriptases, respectively
15-18
. It has been 
documented that these properties are due to the conformational and stereoelectronic 
changes brought about by the replacement of oxygen with sulfur in the heterocyclic ring. 
However, even in these molecules, the sulfur atom does not play a central role in the 
reaction of the molecule with a biological entity. 
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S OH
OH
HO OH
HO
S OHH3C
OH
HO OH
S OH
OH
HO OH
HO
D-5-Thioglucose L-5-Thiofucose D-5-Thiomannose 
Figure (1.9) Thiosugars and Thionucleosides. 
 
In many other cases, however, the bioactivity of an organosulfur compound may be 
directly attributable to the reactivity of the sulfur center, which is certainly the case for 
the sulfur mustards (Fig 9). Here, the sulfur atom is responsible for activating the 
compound toward nucleophilic attack by displacing a chlorine atom and forming an 
episulfonium ion (10). Thus formed, this cationic electrophile is prone to attack by a 
biological nucleophile, and can lead to crosslinking of duplex DNA. 
 
Cl
S
Cl Cl
S
Nu
Cl
S
Nu
10  
Figure (1.10) Sulfur Mustard 
 
1.3.1 Thiol Reagents 
1.3.1.1 Antibacterial Thiols 
Thiol-bearing enzymes often lose some or all of their activity in the presence of non-
native thiols like allyl mercaptan due to the formation of mixed disulfide. Thus, thiol-
bearing therapeutics are often effective at inhibiting enzymatic pathways regulated by 
these proteins. Although there are a large number of small, natural product thiols known 
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to possess antibiotic activities, there are only a few synthetically-derived thiols that have 
been shown to be antibacterial. A trio of thiodiazole aromatics (11) is reported to have 
minimum inhibitory concentrations (MICs) against Staphylococcus aureus in the 31-62 
µg/ml range, but impose no effect on E. coli
19
 (Fig 1.11).  
N
NN
N
S
SH
X X - o-Me, p-Br, p-Cl
11  
Figure (1.11) S. aureus-Active Thiodiazoles. 
A similar effect was observed in case of 1,3,4-thiadiazolium-5-thiolates
20
 (Fig 1.12), 
whose MIC’s against Staphylococcus aureus range from 1-8 µg/ml, and which also 
exhibit moderate activities against E.coli. The mechanism of action of these compounds 
is yet to be studied. 
N
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N
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S
S
R
(a) R = CH3, (b) R = C6H5, 
(c) R = 2-Cl–5-NO2–C6H3, 
(d) R = 3-NO2–C6H4
 
Figure (1.12) Substituted 1,3,4-thiadiazolium-5-thiolates 
1.3.1.2 Antifungal Thiols 
Due to the proliferation of thiol-bearing enzymes in a large majority of life forms, it is to 
be expected that anti-infective thiol compounds could be found in Nature that can 
successfully inhibit the growth of fungi by formation of mixed disulfides. Most of the 
previously discussed antibacterial thiols have been observed to possess some antifungal 
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activity. Closely related derivatives of the antibacterial mercaptotriazoles (12) inhibit 
Candida albicans and Saccharomyces cerevisiae, with minimum fungicidal concentration 
(MFC) values in the range of 12.5 to 61 µg/ml
21
. Both the thiol and amine groups are 
believed to be required for antifungal activity, since the thiodiazole aromatics (which lack 
the amino moiety) and their precursors have no antifungal properties. 
R
N
NN
SH
NH2
R - 3-Br, 4-CH3, 4-OCH3
12  
Figure (1.13) Mercaptotriazole antifungals 
 
A new class of 1,3,4-oxadiazole compounds (13) have reportedly shown growth 
inhibition zones of 20-25 mm at 100 µg, equivalent to the control antifungal compound 
griseofulvin. 
N
N
N
O
R
R'
HS
R = p-Cl-C6H4, p-F-C6H4, p-CH3-C6H4
R' = F, Cl, NO2
13
 
Figure (1.14) Antifungal 1,3,4-oxadiazoles 
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1.3.1.3 Antiviral Thiols 
Intracellular redox activity controls replication and virulence of viruses
22
. The cellular 
thiol, glutathione, itself has purported in vitro and in vivo anti-influenza activity. As 
levels of glutathione are depleted in mucosal cells lining the oral, nasal and upper 
airways, susceptibility to viral infection is enhanced. Decreased intracellular glutathione 
levels are also implicated in Human Immunodeficiency Virus (HIV) infections, and 
methods to increase glutathione production, in human monocyte derived macrophages 
and lymphocytes, have been proposed as a means to stop these infections
23-25
. N-Acetyl-
L-cysteine (NAC) and 2-mercaptoethylamine (MEA) have been shown to strongly 
increase glutathione levels in various cell lines
26
. Several new N-(N-acetyl–L-cysteinyl)-
S-acetylcysteamine derivatives (Fig 1.15) have also been reported to actively release 
NAC and MEA intracellularly, which in turn improve glutathione levels. 
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Figure (1.15) S-Acetylcysteamine derivatives 
These compounds display an EC90 (effective concentration for 90% inhibition of virus 
yields) ranging from 80 to 380 µM against HIV in human monocyte-derived 
macrophages (MDM). S-Acylated derivatives are believed to have increased activity by 
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1) having a protected thiol and 2) increasing lipophilicity relative to the free thiol. 
Another way reported to protect a free thiol is by use of a thiocyanate, which is likely 
reduced in vivo to the thiol through an equilibrium exchange with a native thiol such as 
glutathione
27
. Examples of this include a group of thiocyanatopyrimidine nucleosides 
(14), which are reported to display reasonable activity (EC75 = 100 µM) against vaccinia 
virus replication in HeLa cells.  
N
NO
O
SCNH
R
N
NO
O
SHH
R
R'SH
14  
Figure (1.16) Thiocyanatopyrimidine nucleoside (R = ribofuranosyl nucleoside). 
1.3.1.4 Antiparasitic Thiols 
A novel sesquiterpene named T-cadinthiol (15) shows significant antiparasitic 
properties
28, 29
. This terpenoid metabolite, with four fixed stereocenters, displays activity 
towards cultured Plasmodium falciparum, a species of malaria, with an IC50 of 3.6 
µg/ml. The mode of action of this agent is still unexplored, however, and a number of 
derivatives of 15, including the corresponding alcohol analog, were tested and shown to 
have absolutely no biological activity. The thiol group appears to be essential for 
antiparasitic effects.  
SH
H
H
15  
Figure (1.17) Antiprotazoal agent T-Cadinthiol. 
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African trypanosomiasis caused by Trypanosoma brucei gambiense and T. brucei 
rhodesiense was treated with melaminophenylarsine melarsoprol (MelB), introduced in 
1947
30
. MelB is insoluble in water and is administered by intravenous injection as a 
propylene glycol solution. This arsenical agent is frequently associated with a number of 
serious side effects and the solvent is an irritant that often causes thrombophlebitis. 
Water-soluble arsenical agents such as melarsonyl potassium (MelW) showed little 
improvement over MelB. Later a new, water-soluble trivalent arsenical agent, 
melarsamine hydrochloride (MelCy) (trade name: Cymelarsan), was shown to be very 
effective against T. brucei brucei, T. evansi, and T. equiperdum 
31, 32
. A successful 
attempt to increase the activity of this drug, by derivatizing the thiol groups to get the 
level of affinity between arsenic and sulfur atoms optimal for biological activity, has been 
reported
33
. The most active thiol system is the propane-1,3-dithiol (2-melarsenyl).  
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Figure (1.18a) Trypanocidal agents 
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In fact, 2-melarsenyl is twice as potent as Cymelasan (MelCy) against Trypanosoma 
brucei brucei strains (0.025 versus 0.05 µM concentration to terminate all growth in 1 
hour). It is believed that in aqueous solution Cymelasan is in equilibrium with the 
hydrolyzed oxide form (melarsen oxide), which has lost thiol groups and thus the 
activity
33
. 
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Figure (1.18b) Equilibrium between Cymelarsan and melarsen oxide in water 
 
1.3.2 Sulfide Reagents 
Penicillin (6), cephalosporins (7) and penems (8), as discussed earlier in this chapter, are 
some of the most potent sulfide anti-infectives. Diallyl sulfide (Fig 1.19), isolated from 
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garlic, is another natural antimicrobial compound which has shown inhibitory activity 
against MRSA in mice.
34
 
S
 
Figure (1.19) Diallyl sulfide, isolated from garlic extract 
 
1.3.2.1 Antifungal Sulfides 
Six newly reported sulfide-bearing 1,4-naphthoquinones (16-21) have been found to 
display good to potent activities against Candida albicans, Cryptococcus neoformans, 
Sporothrix schenckii, Trichophyton mentagraphytes, Aspergillus fumigatus and 
Microsporum cannis, with MFCs ranging from less than 0.78 to 50 µg/ml, a marked 
improvement over their respective oxygen counterparts
35
. As of yet, the mechanism of 
their activity is not understood, but may in fact be related to the oxidative potential of the 
naphthoquinone ring system and not to the presence of the sulfur moieties. 
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Figure (1.20) Antifungal Naphthoquinone Sulfides 
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1.3.2.2 Antiparasitic Sulfides 
Fasciolosis (Fasciola hepatica) is a serious parasitic disease in humans and livestock. 
Few new anti-fasciolitic compounds have been marketed since triclabendazole (TCBZ), a 
benzimidazole used routinely in veterinary medicine since 1983 and for human use, in 
some regions, since 1989, was patented in 1978. A new bioactive derivative of TCBZ, 5-
chloro-2-methylthio-6-(1-naphthyloxy)-1H-benzimidazole (22) has been recently 
discovered
36
. While this analog has an effective dose of 15 mg/kg, the marketed TCBZ 
displays a 5 to 10 mg/kg effective dose against Fasciola hepatica. The mechanism of 
action of this analog has not been elucidated, and the role of the sulfide moiety is not 
known. 
O
Cl N
H
N
S
CH3
22  
Figure (1.21) Methylthiobenzimidazole fasciolicide (22)  
 
1.3.3 Disulfide Reagents 
1.3.3.1 Antibacterial Disulfides 
As therapeutic agents, disulfides usually serve as inactive structural components of 
biomolecules or as biological oxidants. In the latter role, disulfides are particularly prone 
to react with thiols to give biologically-inert mixed disulfide adducts. Many of the leek 
extracts, like Ajoene (23), create the same type of mixed disulfide products with native 
thiols that are seen with the corresponding thiol drugs
37
.  
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When various concentrations of cysteine were added to ajoene-containing media, the 
ajoene concentrations were decreased. Similar effects were also observed with 
dithiothreitol instead of cysteine. The sulfhydryl groups in cysteine and dithiothreitol are 
highly reactive to disulfides and tend to form mixed disulfides, which are biologically 
inactive. This likely explains the decrease in concentration of ajoene and inhibitory 
activity towards various pathogens. 
38
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Figure (1.22) Formation of mixed disulfides of Ajoene. 
 
Epipolythiodioxopiperazines (ETP’s) are a class of fungal metabolites of Candida, 
Thermoascus and Penicillium, to name a few, that possess characteristic bridged disulfide 
piperazinedione six-membered rings. These antibiotics only inhibit Gram-negative 
bacteria, which are likely related to their outer membrane permeability, and are prone to 
nucleophilic attack on their electrophilic disulfide bridge. Gliotoxin (24) and related 
ETP’s are reported to act as oxidants by at least two different pathways: 1) generation of 
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superoxide and hydrogen peroxide via glutathione redox cycling, and 2) sulfenylation of 
native thiols of certain proteins to make catalytically defunct mixed disulfides
39, 40
. Which 
sulfur center in gliotoxin is the site of enzymatic attack is still unclear but it is likely that 
both may be involved. 
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24  
Figure (1.23) Gliotoxin, an Epipolythiodioxopiperazine (ETP) antibacterial reacts with 
thiols. 
 
Isolated from both a species of Psammaplysilla and Thorectopsamma xana, a trio of 
closely related disulfides was discovered with antibacterial activity
41
. Psammaplin A (25) 
and the dimer, Bisaprasin (26), along with Psammaplin D (27) all inhibit growth of 
Staphylococcus aureus and Bacillus subtilis. Psammaplin D also shows activity against 
the Gram-negative bacterium Trichophyton mentagraphytes
42
. 
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Figure (1.24) Psammaplin A 
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Figure (1.25) Bisaprasin 
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Figure (1.26) Psammaplin D 
 
Isolated from a tunicate, Polycitorella mariae, a novel disulfide termed Citorellamine 
(28), has been reported to have significant antimicrobial activity
43
. Originally assigned 
the structure of a sulfide, the disulfide Citorellamine demonstrates potent antibacterial 
activity against Staphylococcus aureus, Bacillus subtilus and Escherichia coli as well as 
cytotoxicity in some cancer cell lines
44
.  
Disulfides with interesting antibacterial activities also occur in proteins specifically 
synthesized by life forms for defense. These antibiotics are found most commonly in 
marine sources, and usually contain two neighboring cysteine residues. One such 
antibacterial protein, from a marine decapod, displayed potent inhibition of Planococcus 
citreus, Planococcus kocurii, Aerococcus viridans, and Micrococcus luteus and an 
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extraordinarily strong resistance to heat damage due to the presence of disulfide bonds
45
. 
It was found to be cationic, yet hydrophobic, with a molecular mass of about 11.5kDa. 
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28  
Figure (1.27) Citorellamine 
A series of simple aryl–alkyl disulfides have also been looked at previously in the Turos 
lab. These aryl–alkyl disulfides
46
 demonstrated strong in vitro antimicrobial properties 
against S. aureus, MRSA and B. anthracis. The nitrophenyl alkyl disulfides exhibited the 
most in vitro potency, and bioactivity seems to require that the aryl substituent (X) be 
electron-withdrawing.  
SH
X
S
X
SRRSSO2Me
MeOH
X - F, CH3, OCH2CH3, CH2OH, NHAc, NH2, NO2
R - Me, Et, nPr, iPr, nBu, s-Bu  
Figure (1.28) Aryl-alkyl Disulfides synthesized in Dr.Turos’ lab. 
 
In vitro microbiological properties of these compounds, determined from agar diffusion 
and agar MIC measurements, coincides with the FabH inhibition capabilities, which 
points to the likelihood that this key bacterial enzyme is associated with the biological 
properties of the disulfide compounds. 
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1.3.3.2 Antifungal Disulfides 
Although the mechanism of action of the organodisulfide, Ajoene (23) is still under 
active investigation, it is likely that antifungal activity is the result of induced cell wall 
damage, since morphological changes in fungal cells treated with these compounds have 
been observed via scanning and transmission electron microscopy
47
. Disulfides are 
commonly found as toxins produced by fungi
48
, however, two groups of disulfides having 
antifungal activity have been reported
49-51
. The first group of compounds contains some 
of the most potent antifungal agents ever known, the thiarubines (29), with MIC’s in the 
ng/ml range 
49
. Isolated as natural products from the Compositae (Asteraceae) family of 
plants, the thiarubines display activities against Cryptococcus neoformans, Aspergillus 
fumigatus, Candida albicans and other species of Candida. 
 
S S
R R'
29  
Figure (1.29) Core Structure of the Thiarubine Group of Antifungals. 
 
The tunicate-generated disulfide, Citorellamine (28), not only possesses strong 
antibacterial activity, but is also very active against Saccharomyces cerevisiae and mildly 
active towards Pseudomonas aeruginosa 
43, 44
. The other group of disulfides, the 1,2-
dithiole-3-thiones (30), is very interesting because it consists of compounds that could 
possibly behave as a disulfide, sulfide, or thiol in its activity
50
. The compounds are 
fungicidal against Candida albicans, Candida tropicalis, Cryptococcus neoformans, 
Sacharomyces cerevisiae, Aspergillus fumigatus, Aspergillus flavus, Aspergillus niger, 
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Microsporum cannis, Microsporis gypseum, Epidermophyton floccosum, Trichophyton 
rubrum and Trichophyton mentagrophytes. The main activity is due to the disulfide-
thione functionality. Although the pendant sulfide (SR) is not strictly required for 
activity
51
, its presence, as compared to alkyl or aryl groups, increases activity greatly. 
After lengthening the sulfur side chain beyond ethyl, an inverse relationship between 
chain length and antifungal activity begins to develop. However, against all of the fungi 
tested the thiobenzyl analog maintained the greatest potency, with MFC’s ranging from 
0.7 to 6.25 µg/ml. 
 
S
S S
S
R
R = ethyl, propyl, butyl, hexyl, decyl, dodecyl, phenyl, benzyl, cyclopentyl
30
 
 
Figure (1.30) Dithiole-Thione antifungals. 
 
1.3.3.3 Antiviral Disulfides 
As discussed in relation to antibacterials, organodisulfides can act as in vivo oxidants of 
thiols. It is likely that disulfides, and their related thiosulfonates, behave in the same 
manner in terms of their activity in viral systems. A group of aromatic disulfides and a 
thiosulfonate have been reported with potent antiviral activities against the arena viruses 
Junin (JUNV), the causative agent of Argentine hemorrhagic fever, and Tacaribe 
(TCRV)
52
. The disulfides and thiosulfonate (31-34) displayed 50% effective 
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concentration (EC50) values, the concentration at which 50% of the viral yield is 
eliminated, ranging from 3.6 to 100 µM towards these microbes. This is at least ten times 
lower than the concentrations needed to induce cytotoxic effects.  
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Figure (1.31) Antiarenavirus disulfides. 
A large focus of preclinical and clinical development of anti-HIV drugs is in protease 
inhibition. However, other processes are certainly important to viral infectivity and 
replication. Metabolic pathways of infected cells, such as precursor protein processing, 
have been shown to be inhibited by a macrocyclic disulfide (35), 7-methyl-6,7,8,9-
tetrahydrodibenzo [c,k] [1,2,6,9]-dithiadiazacyclododecine-5,10-dione
53
. This compound 
displays an EC50 of 0.05 µg/ml against HIV-infected macrophages, compared to the 
current standard AZT (3’-azido-3’-deoxythymidine) that has an EC50 of 0.004 µg/ml. 
  
26 
 
With a different mode of action from AZT however, the disulfide acts synergistically 
with AZT when tested in vitro, and could potentially be used in combination.  
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35  
Figure (1.32) Anti-HIV macrocyclic disulfide. 
Another disulfide with promising antiviral properties is 5,5’-diphenyl-3,3’-diisothiazole 
disulfide (36a) (DID)
54
. DID induces potent inhibition of plaque-infected cells derived 
from invasion of poliovirus type 1, with an IC50 of 0.35 µM. Cytoxicity to healthy human 
cells was also examined, and no adverse effects were observed with uninfected cell 
cultures at 50 µM concentration of DID. This agent is believed to inhibit an enzyme 
associated with RNA synthesis. 50% cytotoxic concentrations (CC50), the concentrations 
where normal human cell proliferation is inhibited by 50%, were more than 200 times 
higher that the IC50’s, illustrating the exquisite selectivity this compound has for the viral 
infected cells
55
. The reduced form, thiol 36b, has almost the same activity and selectivity 
as 36a (Table 1.1). 
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SS
36a 36b  
Figure (1.33) 5,5’-Diphenyl-3,3’-diisothiazole disulfide and thiol antipoliovirus agents. 
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Table 1.1 Isothiazole anti-poliovirus activities. 
Compound IC50  (µM) CC50  (µM) Selectivity 
CC50/ IC50 
36a 0.35 89.28 255 
36b 0.42 90.75 216 
 
HIV reverse transcription (HIV-RT) and deoxyribonucleoside triphosphate (dNTP) 
synthesis are paramount to viral replication, and thus are prime inhibition targets for anti-
HIV therapy
56
. A number of sulfur-bearing nucleotide HIV-RT inhibitors, which have 
similar effects to AZT, include 3’-mercapto-2’,3’-dideoxynucleotides (37) and 2’- deoxy-
2’-mercaptouridine-5’-diphosphate (38)
57, 58
. These nucleosides serve to transfer a radical 
to a thiol of the transcriptase as shown in Fig 1.33.  
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Figure (1.34) Dideoxynucleotides thiyl radical-based reverse transcriptase inhibitors. 
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Figure (1.35) Postulated mechanism of reduction of natural ribonucleoside 5’- 
diphosphates. 
 
A new pyrimidine nucleoside disulfide (39) has been synthesized and shown to inhibit 
both HIV-RT and dNTP. The disulfide also has an EC50 of 10 µM and an IC50 of 25 µM 
against proliferation of human T-lymphocyte cells. Very interestingly, the corresponding 
thiol derivative had no activity at all.  
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Figure (1.36) Mercaptouridine Thiyl Radical-based Reverse Transcriptase Inhibitors. 
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Figure (1.37) Nucleosidic disulfide anti-HIV agent. 
 
1.3.4 Trisulfide Reagents 
1.3.4.1 Antibacterial Trisulfides 
Trisulfides found in garlic, such as diallyl trisulfide and allyl methyl trisulfide (Fig 1.38), 
can act as antibacterial agents in the same way as disulfides, but with greater efficacy.  
 
S
S
S
S
S
S
Diallyl trisulfide Allyl methyl trisulfide 
Figure (1.38) Anti-infectives from garlic 
 
The antibacterial activity of some cyclic polysulfides like tetrathiepanes can be attributed 
to a trisulfide bridge, as much as previous examples owe their activity to a disulfide 
bridge
48, 59
. 4-Dioxo-1,2,4,6-tetrathiepane (40), an extract from the red alga Chondria 
californica, has potent antibacterial activity against Vibrio anguillarium, the causative 
agent of a tropical fish disease. 
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Figure (1.39) 4-Dioxo-1,2,4,6-tetrathiepane. 
Also part of the trisulfide family of antibiotics are the enediyne trisulfide 
antitumor antibiotics, calichaemycin (41a), a natural product of Micromonospora 
echinospora, Namenamicin (41b), and esperamicins, natural products of Actinmadura 
verrucosospora. Calichaemycin is at least a thousand times more potent than penicillin G 
against S. aureus. Although these antibiotics are not currently used to treat infection 
because of their elevated toxicity, in anticancer studies these compounds have been 
shown to undergo an intricate cascade of intramolecular reactions initiated by glutathione 
attack, resulting in an intensely reactive radical species.  
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Figure (1.40) Enediyne Trisulfides:  Calichaemycin (41a), Esperamicin A1 (41b) and 
Namenamicin (41c). 
 
In the first step of this process, reaction of the trisulfide group with glutathione generates 
a free thiolate anion which in turn undergoes a Michael addition across the α,β-saturated 
ketone. This subtle change in orbital hybridization of the carbons allows the enediyne to 
undergo Bergman cycloaromatization, producing the phenylene diradical
60
.
 
These 
diradicals are believed to cleave DNA by sequentially stripping off hydrogen atoms along 
the minor grove of the double helix. Even though their mechanism of antibacterial action 
has not been proven to be the same as that of the anticancer mechanism, it is likely that 
the trisulfide moiety is involved as an electrophilic reactant with cellular thiols (Table 
1.2). 
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Figure (1.41) Bioactivation of Enediynes   
 
Table 1.2 Enediyne Antibacterial Activities 
MIC(µg/ml)  
Bacteria Calichaemycin Namenamicin Penicillin G 
Bacillus subtilis  0.00005  0.03  0.25  
Staphylococcus aureus  0.000001  0.001  0.015  
Enterococcus faecium  0.00012  0.03  128  
Escherichia coli  0.12  0.12  32  
Klebsiella pneumoniae  0.25  0.06  128  
 
1.3.4.2 Antifungal Trisulfides 
Although not currently used in clinical settings, enediyne antitumor antibiotics also 
display potent antifungal activities. Candida albicans, Ustilago maydis, Saccharomyces 
cerivisiae, and Neurospora crassa are all inhibited by Calicheamicin and Namenamicin 
with MIC’s below 1 µg/ml
61
. Their mechanism of action is presumably similar to that of 
their antibacterial and anticancer properties as DNA cleaving agents triggered by S-
thiolation of glutathione or a related cellular thiophile. 
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Table 1.3 Enediyne Antifungal Activities 
MIC  (µg/ml)  
Fungus  Calichaemycin Namenamicin  
C. albicans  0.03  0.25  
U. maydis  0.001  0.004  
S. cerevisiae  0.008  0.06  
N. crassa  0.06  0.25 
 
1.3.5 Polysulfide Reagents 
1.3.5.1 Antibacterial Polysulfides 
Within the Didemnidae or tunicate family, Lissoclinumi species are rich sources of 
organosulfur antibiotics. One such isolate, Lissoclinotoxin A (42), demonstrated potent 
growth inhibition of a number of bacteria, including S. aureus, Streptococcus faecalis, 
Cirrobacter species, Klebsiella species, E. coli, Enterobacter species, Serratia species, 
Salmonella species, Pseudomonas aeruginosa, Acinetobacter, and Proteus species
62
. 
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Figure (1.42) Lissoclinotoxin A. 
 
1.3.5.2 Antifungal Polysulfides 
Lissoclinotoxins A (42) and D (43) (disulfide analog), pyridoacridine alkaloids from 
ascidians, both display potent antifungal activities against Candida albicans and 
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Trichosporon mentagrophytes, with cell-mediated immunity levels (CMI) of 40 and 20 
µg/ml, respectively.  
OCH3
HO
NH2
S S
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43  
Figure (1.43) Lissoclinotoxin D. 
 
1.3.5.3 Antiparasitic Polysulfides 
Another anti-malarial agent, Lissoclinotoxin A (42) has also demonstrated potent activity 
towards a resistant strain of the parasite Plasmodium falciparum
62
. Lissoclinotoxin A is 
intermediate in activity compared to the usual antimalarials quinine, mefloquine, 
halofantrine and chloroquine, with an IC50 of 296 nM (Table 1.4). Although not yet 
defined conclusively, its mechanism is likely similar to that described for di- and 
trisulfide antibacterials.  
Table 1.4 Anti-malarial activities of Lissoclinotoxin A and a few clinical standards. 
Anti-Malaria Agent  IC50 
(nM)  
Lissoclinotoxin A (42)  296  
Quinine  350  
Mefloquine  40  
Halofantrine  2  
Chloroquine  580  
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1.3.6 Other Organosulfur agents 
1.3.6.1 N-Thiolated Antibacterials 
N-Sulfenylated monocyclic β-lactams (44) are another class of sulfur-containing 
antibacterial compounds recently discovered to have an unusual mode of action, where 
the N-S functionality may interact with cellular thiols in the same fashion as a disulfide
63
. 
Regardless of the presence of a β-lactam ring, the mode of action of these N-thiolated 
compounds
64
 is totally different to that of the penicillins and other beta-lactam drugs, 
which act as cell wall biosynthesis inhibitors.  
 
N
O S
R2O
R1
R3
44  
Figure (1.44) N-Sulfenylated-β-Lactam Antibacterials 
 
It is believed that an intracellular thiol in susceptible bacteria, coenzyme A, attacks the 
sulfur atom to form a mixed disulfide which in turn causes inhibition of bacterial growth 
by blocking lipid biosynthesis. These thiolated lactams show a narrow range of 
antibacterial properties, including Staphylococcus strains such as MRSA and S. 
epidermidis, with MIC’s as low as 0.125 µg/ml. 
 
  
36 
 
N
OS
R2 O R1
R3
P
O
OH
O
O
P
O
HO
HN
H
N
SH
O
O
HO
O
O
P
O
HO
OH
HO
NN
N
N
NH2
O
P
O
OH
O
O
P
O
HO
HN
H
N
S
O
O
HO
O
O
P
O
HO
OH
HO
NN
N
N
NH2
O
S
R3
NH
O
R2O
R1
 
Figure (1.45) Formation of CoA – β-lactam mixed disulfide. 
 
Another sulfenamide, 1,2-benzoisothiazolin-3-one (BIT) (45), has shown weak activity 
against Staphylococcus aureus, with an MIC around 100 µg/ml [57].  
S
NH
O
45  
Figure (1.46) BIT. 
BIT has been shown to inhibit the action of a number of intracellular thiols such as 
glutathione and ATPase. The mode of action has been linked to an inhibitory effect on 
cellular respiration upon metabolic uptake. Lansoprazole (46), a drug designed as a 
gastric acid pump inhibitor, has been shown to rearrange in the acidic environment of the 
stomach to a sulfenamide (47), which is an inhibitor of Helicobacter pylori 
65
. H. pylori is 
considered to be a main culprit in the cause of gastric ulcers and therefore lansoprazole 
serves double duty as an antibiotic and an acid production reducer.  Even though an 
intermediate sulfenic acid derivative of lansoprazole also displays anti-pylori activity, the 
sulfinamide affords fast action with an MIC value of 10 µg/ml.  
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Figure (1.47) Lansoprazole and in vivo Sulfenamide. 
 
1.4 Conclusions 
This chapter discusses the various classes of organosulfur compounds which have shown 
efficient antimicrobial activities against bacteria, viruses, fungi and various parasites. 
Most of these compounds are either made by Nature or inspired from them. The mode of 
action of the majority of these organosulfur compounds has not been defined and requires 
further investigation. One of the rich sources of natural organosulfur compounds is 
Allium sativum (garlic), which has potent antibacterial and antifungal activity. A major 
inevitable problem with bacteria is the development of antibiotic resistance. The scope of 
these organosulfurs as clinical anti-infectives could possibly be improved if they could be 
functionalized innovatively to circumvent the resistance mechanisms or act in multi-
modal ways. 
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CHAPTER TWO 
 
SYNTHESIS AND ANTIMICROBIAL ACTIVITY OF S, S’-
HETEROSUBSTITUTED DISULFIDES 
 
 
2.1 Introduction 
The concern over multidrug-resistant bacteria and the need for more effective 
antibacterials has reached a critical level, given that successful treatment of common 
bacterial infections can no longer be taken for granted. Staphylococcus aureus (Staph), a 
gram-positive facultative anaerobe, resides in the nostrils and on the skin of human 
beings. S. aureus starts to cause infection once it enters the blood stream. Antibiotic-
resistant variants of S. aureus, mainly methicillin-resistant Staphylococcus aureus 
(MRSA), is the single most important pathogen causing infections. The mutants from the 
community, referred to as community-acquired MRSA (CA-MRSA), are known to be 
more lethal and complex in nature than the variants originating in hospitals, which are 
referred to as hospital-acquired MRSA (HA-MRSA). MRSA is known to cause infections 
of skin and soft tissue
66
, as well as pulmonary,
67
 osteoarticular
68
, hemorrhagic adrenal 
gland (Waterhouse-Friderichsen syndrome
69
) and opthalmic infections
70
. According to 
the United States Centers for Disease Control and Prevention (CDC), MRSA accounted 
for more than 94,000 life-threatening infections and nearly 19,000 deaths in the United 
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States alone in 2005
71
. CDC also emphasizes that the prevalence of multi-drug resistant 
bacteria is rising at an alarming rate.  
The Turos laboratory has been studying the effects of a variety of synthetic 
antibacterial agents against common microbes. Previously we have investigated N-
thiolated β-lactams
64, 72-77
, N-thiolated 2-oxazolidinones
78
 and recently, a novel family of 
aryl-alkyl disulfides,
46
 are which all effective growth inhibitors of MRSA. The mode of 
action and structure–activity profiles of all these substances differ dramatically from 
those of other analogs of β-lactams, oxazolidinones, and disulfides. Investigations in our 
laboratory
 
have shown that these compounds can each carry a wide range of substituents, 
and are reactive towards thiophilic agents under certain conditions (such as in bacterial 
cytoplasm).  
N
O SMe
R2R1O
O N
O
R1 R2
SMe
S
SR2
N-Thiolated   -lactams N-Thiolated oxazolidinones
R1
Aryl-alkyl disulfidesβ  
Figure (2.1) Various antibacterials synthesized in the Turos lab. 
 
The aryl–alkyl disulfides were looked at previously in the Turos lab by Dr. Kevin Revell, 
and found to have strong in vitro antimicrobial properties against S. aureus, MRSA and 
B. anthracis. The nitrophenyl alkyl disulfides exhibited the most in vitro potency.  
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SH
X
S
X
SRRSSO2Me
MeOH
X - F, CH3, OCH2CH3, CH2OH, NHAc, NH2, NO2
R - Me, Et, nPr, iPr, nBu, s-Bu  
Figure (2.2) Various aryl-alkyl disulfides synthesized in the Turos lab. 
 
The fact that the in vitro microbiological properties of these disulfides, determined from 
agar diffusion and agar MIC measurements, coincides with the FabH inhibition 
capabilities points to the likelihood that this key bacterial enzyme is associated with the 
biological properties of the compounds. More detailed studies into this are now being 
done in collaboration with Dr. Lindsey Shaw’s laboratory in the USF Biology 
department.  
This chapter describes experiments on a series of new sulfur-containing 
antibacterials, S,S’-heterosubstituted disulfides. In this study, we investigated the 
synthesis and antibacterial and antifungal properties of these structurally intriguing 
compounds. 
2.2 Synthesis  
These investigations were initiated by the synthesis of a group of S,S’-heterosubstituted 
disulfides shown in figure 2.2. These compounds were chosen as a means to assess the 
electronic effects of different heteroatoms on bioactivity. These derivatives were 
prepared by treating an alcohol, amine or thiol with sulfur monochloride at -20 °C in the 
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presence of triethylamine as a Lewis base (Fig 2.3). The desired disulfide products were 
obtained in 70-90% yields after column chromatography, and characterized by 
1
H NMR 
spectroscopy. 
 
RXH
S
-20 oC - rt
CH2Cl2
( X = O, N, S )
Base
S
Cl
Cl
SS
RX
XR
 
Figure (2.3) Synthesis of S,S’-heterosubstituted disulfides. 
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Figure (2.4) Synthesized S,S’-heterosubstituted disulfides. 
 
2.3 Elucidation of 
1
H NMR spectrum of di sec-butoxy disulfide (1d): 
The structure of the disulfide products 1-4 were determined by 
1
H NMR spectroscopy. 
The 
1
H NMR spectrum of di-sec-butoxy disulfide (1d) is illustrated below as a 
representative example (Fig 2.5). Apart from the obvious lack of the alcohol O-H peak in 
1
H NMR spectrum (from the starting alcohol), the chemical shifts of the disulfide protons 
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are slightly downfield as compared to those of sec-butanol. This can be attributed to the 
presence of the oxygen-sulfur bond which deshields the neighbouring protons more than 
in the case of the alcohol, due to the electronegativity of the O-S bond.  
 
 
Figure (2.5) 
1
HNMR spectra of sec-butanol and di sec-butoxy disulfide (1d). 
 The protons of carbon-4 of butanol (marked in red) have a chemical shift of 0.70-0.76 
ppm and appear as a clearly-defined triplet whereas in the disulfide they appear as an 
  
44 
 
unresolved multiplet at 0.83-0.91 ppm. The C-1 methyl protons appear as a doublet at 
1.17-1.23 ppm in case of the disulfide and at 0.97-0.99 ppm for the alcohol. The 
methylene protons show up at 1.46-1.61 ppm as a multiplet for the disulfide and at 1.22-
1.31 ppm in case of the alcohol. And finally methine (–CH) proton appears at 3.77-3.86 
ppm for the disulfide and at 3.49-3.56 ppm in the alcohol. Similar trend was observed in 
rest of the disulfides. 
2.4. Reactivity of S,S’-heterosubstituted disulfides 
The reactivity of S,S’-heterosubstituted disulfides has been previously explored 
by Motoki
79
 etal. Dialkoxy disulfides reportedly react with mercaptans or secondary 
amines (Fig 2.6) at reflux conditions in carbon tetrachloride to give alkoxy alkyl 
trisulfides (2) or alkoxy amino disulfides (3) with elimination of alcohol. The yields are 
typically below 50% for reactions with thiols, and 22-74% for amines. 
ROSSORROSSSR'
R
O
S
S
N
R"
R"
1
2 3
HN
R"
R"R'SH 50 C°
CCl4   3hrs
22% - 74%
Reflux
CCl4  4hrs
22% - 50%
 
Figure (2.6) Reactivity of dialkoxy disulfides with thiols and secondary amines. 
 These alkoxy alkyl trisulfides (2) further react with mercaptans or secondary amines at 
refluxing conditions in carbon tetrachloride to give unsymmetrical dialkyl tetrasulfides 
(4) and alkylamino trisulfides (5) in varying yields.  
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Figure (2.7) Reactivity of alkoxy trisulfides (2) with thiols and secondary amines. 
 
The alkoxy diamino disulfides (3) also react with thiols and amines in the similar fashion 
(Fig 2.8) to yield alkylamino trisulfides (5) and unsymmetrical diamino disulfide (6), 
respectively. 
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Figure (2.8) Reactivity of alkoxy amino disulfides (3) with thiols and secondary amines. 
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Motoki found that when diethoxy disulfide was reacted with 1,1-disubstituted 
thioureas, thiadiazoles (7) were obtained, whereas 1,3-disubstituted thioureas yielded 
carbodiimides (9) in moderate yields.
80
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Figure (2.9) Reactivity of dialkoxy disulfides (1) with 1,1 and 1,3- disubstituted 
thioureas. 
Motoki etal. also studied the reactions of diethoxy disulfide with various arylhydrazines 
(Fig 2.10). Diethoxy disulfide on refluxing with arylhydrazines in benzene loses ethanol 
and yields aryl ethoxy tetrasulfides (10), aryl benzenes and diaryl sulfides.
81
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Figure (2.10) Reactivity of dialkoxy disulfide (1) with monosubstituted hydrazine. 
All these compounds were purified either by recrystallization or column chromatography 
and characterized by elemental analysis and 
1
H NMR spectroscopy. A detailed look at the 
various reaction conditions can be seen in table 2.1. 
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Table (2.1) Reaction of diethoxy disulfide with monosubstituted hydrazine. 
Hydrazine 
(ArNHNH2) 
Ar 
Benzene 
refluxing time 
(hrs) 
Products- Isolated yields (%) 
Ar-C6H5                               Ar-S4-OEt              Ar-Sn-Ar 
4-NO2C6H4 10 21 29 13 (n=2) 
2-Cl-C6H4 30 27 10 48 (n=4) 
4-BrC6H4 20 0 5 39 (n=4) 
C6H5 12 8 0 37 (n=4) 
4-CH3C6H5 15 20 0 31 (n=4) 
2-C10H7 15 5 0 47 (n=4) 
 
2.5. Antimicrobial activity 
The antimicrobial activity of these S,S’-heterosubstituted disulfide compounds 1-
5 (Fig 2.2) was evaluated against a selection of available common bacteria by 
determination of the minimum inhibitory concentration (MIC), Kirby-Bauer diffusion 
assay and  growth viability assay. Minimum fungicidal concentration (MFC) and viability 
assays were also performed against the fungus, Candida albicans. 
2.5.1. Determination of the minimum inhibitory concentrations of disulfides against 
bacteria 
According to the National Committee for Clinical Laboratory Standards 
(NCCLS), the MIC is the lowest concentration of antimicrobial agent that completely 
inhibits visible growth of the organism as detected by the unaided eye. The minimum 
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inhibitory concentrations of the S,S`-heterosubstituted disulfides were evaluated against 
Staphylococcus aureus (S.A - ATCC 25923) and a methicillin-resistant strain of 
Staphylococcus aureus (MRSA – ATCC 43300) by Danielle Gergeres in Dr. Turos’ lab 
by agar dilution using a 24-well plate. This was done by allowing the bacteria to grow for 
24 hours in presence of varying concentrations of antibiotic. All the antimicrobial assays 
were performed in triplicate. Penicillin G was used as a positive control and DMSO as 
negative control in all these assays. The averaged MIC values of the S,S`-dialkoxy 
disulfides are shown in table 2.2. For this series, antibacterial activity improved with the 
increase in the chain length, with exception for the sec-butoxy derivative. The most 
active of the five analogs is the isopropoxy compound (1b).  
Table (2.2) MIC’s of S,S’-dialkoxy substituted disulfides. 
SS
RO
OR
 
 Compound             R       S.A MRSA 
           (µg/mL) 
  1a   propyl   32 32 
  1b   isopropyl  1 0.5 
  1c   butyl   0.25 8 
  1d   s-butyl   16 8 
  1e   phenyl   2 2 
 
The activity among the thiol substituted disulfides (Table 2.3) decreases with increase in 
the alkyl chain branching. Surprisingly these compounds were not as active even with the 
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presence of four sulfur atoms, indicating that the number of sulfur atoms is not directly 
related to the antibacterial activity.  The phenyl substituent (2e) was found to provide the 
greatest potency among the five R substituents examined. In general, the activity 
decreased with the increase in the hydrophobic nature of the chain. In case of the S,S’-
diamino disulfides (3a-e), those made from primary amines (Table 2.4) have weaker 
activity than those of secondary amines (Table 2.5).  
 
Table (2.3) MIC’s of S,S’-dithio substituted disulfides. 
SS
RS
SR
 
 Compound             R       S.A MRSA 
             (µg/mL) 
  2a   propyl   32 32 
  2b   isopropyl  32 32 
  2c   butyl   64 32 
  2d   s-butyl   32 64 
  2e   phenyl   8 8 
 
 
 
 
 
 
  
50 
 
Table (2.4) MIC’s of S,S’-diamino substituted disulfides. 
 
SS
N
N
R
H
R
H
 
 
 Compound            R       S.A MRSA 
           (µg/mL) 
  3a   propyl   8 4 
  3b   isopropyl  32 32 
  3c   butyl   8 32 
  3d     s-butyl   16 16 
  3e   phenyl   4 4 
 
For the S,S’-diamino substituted disulfides also, the most active compound was the 
phenyl substituted one, followed by the propyl. Compound 4a, synthesized from the 
dimethylamine, showed potent activity among the secondary amine disulfides. Increase in 
the chain length and branching only resulted in the loss of activity in this case. In 
comparision the S,S’-diamino disubstituted disulfides had a smaller range of MIC values 
than the other analogues.  
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Table (2.5) MIC’s of S,S’-diamino disubstituted disulfides. 
SS
N
N
R
R
R
R
 
 Compound             R       S.A MRSA 
           (µg/mL) 
4a   methyl   0.25 0.5 
  4b   ethyl   2 2 
  4c   isopropyl  2 1 
  4d    allyl   1 0.5 
  4e   isobutyl  16 16 
 
Apart from varying the alkyl chains on the heteroatoms, we also wanted to 
observe the effects of chirality on the bioactivity. To accomplish this, various chiral 
alcohols and amines were used as substrates for the reaction with sulfur monochloride. It 
was observed that the activities of the chiral disulfide analogs 5 & 6 (Table 2.6) were not 
much different from their racemic counterparts. This was observed in case of sec-butyl 
and menthyl disulfide analogs 5a-g. Starting materials for compounds 5c, 5d and 5g were 
racemic mixture of diastereomers, while the rest were optically pure. 
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Chiral analogs:  
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Figure (2.11) Synthesized chiral S, S’- diheterosubstituted disulfides. 
 
Table (2.6) MIC’s of Chiral disulfides 5&6. 
Chiral Substrates   Compound         R                          S.A MRSA 
               (µg/mL) 
Alcohols 
   5a  (S) - s-butyl   16 32 
   5b  (R) - s-butyl   16 32 
   5c  1-phenylpropyl  16 32 
   5d  2-phenylpropyl  16 16 
   5e  (1S, 2R, 5S)-(+)-menthyl 8 8  
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   5f  L(-)-menthyl   8 16 
   5g  (+)-menthyl   8 16 
Amines 
   6a  (R)-benzyl-(1-phenylethyl) 16 64 
   6b  (S)-benzyl-(1-phenylethyl) 16 64 
 
2.5.2 Bacterial Viability Assay 
A bacterial viability assay was carried out by Sonja Dickey in Dr. Daniel Lim’s lab in the 
Department of Biology, University of South Florida, to further assess the antibacterial 
activity of the most active compound, diisopropoxy disulfide (1b). This assay was 
conducted by counting the viable bacterial cells before and after incubation. The initial 
plate count in all tubes was 10
5 
cfu/ml. Staphylococcus aureus 25923 and MRSA 43300 
used as test microbes showed a 3-log increase in the number of bacteria in the absence of 
the disulfide. Diisopropoxy disulfide (1b) was tested against S. aureus 25923 and MRSA 
43300 in concentrations of 2 and 4 µg/ml. In the tubes with 2 µg/ml disulfide, S. aureus 
25923 was decreased in number of cells by one log, but still not all were killed.  In the 
MRSA 43300 2 µg/ml tube, it appears that the cell number increased by one log. In fact 
there were too many cells (>1200 cfu/ml) to count on those plates; and since plate counts 
are considered accurate only when there are 30 – 300 cells on the plate, this cannot be 
considered an accurate count. In the tubes with 4 µg/ml of disulfide, the number of cells 
decreased by 2 logs in both S. aureus 25923 and MRSA 43300. While there was a 
significant decrease in the number of cells, not all were killed. Even with the growth in 
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the 2 µg/ml MRSA tube, it is still less by 2 logs than the control. Also, the minimum 
inhibitory concentration of diisopropoxy disulfide (1b) is 2 µg/ml since there was no 
visible growth of bacteria in the broth until the concentration of disulfide was lowered to 
1 µg/ml. These factors point towards a bacteriostatic nature of the compound.           
Table (2.7) Bacterial viability assay. 
 Drug Concentration 
(µg/mL) 
Before 
Incubation 
(cfu/mL) 
After Incubation 
(cfu/mL) 
S.aureus 25923 Control (no drug) 2.11 x 10
5
 7.6 x 10
8
 
 4 2.22 x 10
5
 2.04 x 10
3
 
 2 1 x 10
5
 3.86 x 10
4
 
    
MRSA 43300 Control (no drug) 3.09 x 10
5
 4.02 x 10
8
 
 4 2.96 x 10
5
 2.88 x 10
3
 
 2 1 x 10
5
 >1.2 x 10
6
 
 
2.5.3 Anti-staphylococcal assay by Kirby-Bauer testing on agar plates 
In addition to evaluating the biological activity by Kirby-Bauer diffusion assay, 
the effect of various additives on the bioactivity of the dialkoxy disulfides was also 
investigated. The intent was to select one of the most bioactive S,S’-heterosubstituted 
disulfide compound, diisopropoxy disulfide, as a representative for all the testing. Two 
more groups of antibacterials, N-thiolated β-lactams and alkyl-aryl disulfides (Figure 
2.12) previously synthesized in Turos’ lab, were also tested simultaneously. All the 
  
55 
 
experiments were performed against MRSA (ATCC 43300) in Mueller-Hinton agar in 
duplicates. 10µg of 1-isopropyldisulfanyl-4-nitrobenzene, 20µg of acrylic acid 2-(2-
chlorophenyl)-1-methylsulfanyl-4-oxo-azetidin-3-yl ester, 50µg of diisopropoxydisulfide 
(1b) and 10µg of penicillin G were used for the assay. All the assays were performed by 
agar diffusion with 1mg of additive in the centre well. These amounts were considered 
after optimization to obtain comparable zones of growth inhibition for easier comparison. 
O2N
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Figure (2.12) Compounds tested by Kirby-Bauer diffusion assay. 
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Figure (2.13) Kirby-Bauer Assay showing no growth inhibition by DMSO. 
The anti-MRSA activity of diisopropoxy disulfide was neutralized by the presence of a 
free thiol diffusing away from the centre well. This cancelling effect was also observed in 
case of the aryl disulfide and beta-lactam. However penicillin G salt had clear zones with 
no inhibition observed. This inhibition was further confirmed by the absence of zones 
around the wells containing both disulfide and glutathione (GSH) or coenzyme A (CoA). 
Since all the compounds were tested as a solution in DMSO, another assay was 
performed to make sure the solvent did not show any inhibitory activity by itself. As 
expected, DMSO did not induce, nor diminish, activity of the compounds as it diffuses 
outward from the center well (Figure 2.13). 
In assays with compounds containing a free thiol group such as coenzyme A (CoA) 
glutathione (GSH) and cysteine (Cys) the antibacterial activity of the compounds was 
completely cancelled (Figure 2.14). This was evident from the indented regions of growth 
inhibition after 24 hours of incubation. 
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Figure (2.14) Kirby-Bauer assay showing the ability of CoA, GSH and cysteine to inhibit 
antimicrobial effects of the test compounds on MRSA.  
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Figure (2.15) Structures of cysteine, coenzyme A and glutathione. 
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Other additives that were tested as controls included glycine, lysine, valine, isopropyl 
disulfide and triphenylphosphine. There was no inhibition observed in any of these cases. 
This can be attributed to the absence of free thiol (Figures 2.16 & 2.17). In case of 
triphenylphosphine a small zone was observed around its well indicating antimicrobial 
activity. The activity may be due to its ability to reduce disulfides responsible for the 
redox equilibrium in the bacteria. 
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Figure (2.16) Kirby-Bauer assay showing no cancellation effect of diisopropyl disulfide 
by isopropyl disulfide or triphenylphosphine. 
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Figure (2.17) Kirby-Bauer Assay showing no inhibition effect from the amino acids 
valine, lysine and glycine. 
 
2.6 Studies of the mode of action of S,S’-heterosubstituted disulfides 
It can be inferred from the Kirby-Bauer experiments that the interaction between the free 
thiol group of the additives and the S,S’-heterosubstituted disulfides is responsible for the 
inhibition of the biological activity.  
In order to determine the exact concentrations of the coenzyme A and glutathione at 
which they can completely inhibit the activity of S,S’-heterosubstituted disulfides, 
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another Kirby-Bauer assay was performed. In this assay both the disulfide and the 
additive (coenzyme A or glutathione) were added in the same well, using varying 
amounts of the additive, while maintaining a constant initial amount of disulfide.  
Thus, disulfide 1b was added along with 0.25, 0.5, 0.75 and 1 molar equivalent of 
glutathione into different wells cut into the agar in a Petri plate with MRSA (Fig 2.18) 
and incubated for 24 hours at 37 °C. A parallel assay was also done using coenzyme A in 
place of glutathione. There were no zones observed around any of the wells, indicating 
that the concentration of glutathione and coenzyme A required to inhibit the activity of 
compound 1b was less than 0.25 molar equivalents.  
1 : 0.25 1 : 0.5
1 : 0.751 : 1
 
Figure (2.18) Kirby-Bauer assay with compound 1b and glutathione in different molar 
ratios in the same well. 
To explore more on the type of conjugates formed, compound 1b was reacted directly 
with coenzyme A in phosphate buffer solution (pH = ~ 7) at 37 °C. HPLC traces did not 
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show any evidence of formation of a new adduct even after 24 hours. A similar reaction 
was also monitored in an NMR tube. Compound 1b was co-mixed with equimolar 
amount of propane-2-thiol at room temperature and heated to 50 °C for 24 hours. This 
experiment also did not show any change in the starting materials. This finding indicates 
something interesting, in that although the mixture was heated to 50 °C, there was no 
apparent reaction between the disulfide and the thiol; however, there must be a reaction 
occurring between the disulfide and thiol additive in the well (or agar) of the Petri plates 
at 37 °C, since the disulfide completely loses its bioactivity. This suggests the possibility 
of bacterial enzymes influencing the formation of the biologically inactive conjugates, 
perhaps via a thiol transfer process.  
 
Figure (2.19) 
1
HNMR tube experiment of diisopropoxy disulfide and propane-2-thiol in 
CDCl3. 
  
In order to explore the possible mode of action, an experiment was conducted to check if 
the disulfides were interacting with
cells were observed under scanning electron microscope (SEM) before and after the 
treatment with diisopropoxy disulfide. It was observed that there was no change in their 
external morphology. The cell wall looked intact
disrupt or interact with bacterial transpeptidases or any cell wall
compounds were to interact with 
would most likely have been disrupted as what
Figure (2.20) Scanning electron microscopy pictures of MRSA cells before and after 
treatment with diisopropoxy disulfide.
 
2.7 Activity of S,S’-heterosubstituted 
To assess the range of antimicrobial activity, S,S’
evaluated against various other bacteria (
Escherichia coli) and fungus (
Bartonella was carried out
Burt Anderson at the College of Medicine, University of South Florida. 
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 the formation of the bacterial cell wall
, indicating that the compound did not 
-related proteins. If the 
these components, the spherical structure of the cells 
 happens in the case of penicillin G. 
              
 
disulfides against other microbes
-heterosubstituted disulfides were also 
Francisella tulerensis, Bartonella sp., 
Candida albicans). The testing of 
 by John Thomas in the biosafety level (BSL) 3 labs of Dr. 
 
. The MRSA 
 
                     
 
Francisella and 
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2.8 Anti-Francisella activity 
Francisella tularensis is a pathogenic species of gram-negative bacteria and the causative 
agent of tularemia, also known as rabbit fever or “cat scratch fever”. Symptoms of 
tularemia include fever, lethargy, anorexia and signs of septicemia, and in extreme cases 
can cause death. As low as 10-50 cfu
82
 (colony-forming units) are sufficient to cause an 
infection. Due to its high pathogenicity and ease of spread by aerosol they were and still 
are considered for usage in biological warfare
83,84
. Hence F.tularensis is classified as a 
Class A agent by the U.S. government. Class A agents have a moderate to high likelihood 
for large-scale dissemination or a heightened general awareness that could cause mass 
fear and civil disruption. F. tularensis is susceptible to carbapenems, ceftriazone, 
ceftazidime, rifampin and certain macrolides, but a lack of clinical data to recommend 
any of these compounds for clinical use
85
. Moreover, there is broad resistance to 
erythromycin among strains of F. tularensis subspecies holarctica
86
. Ciprofloxacin is the 
only drug that is considered ideal for the treatment of tularemia and it may not be long 
before antibiotic resistance mechanisms initiate. In addition, very little is known about 
the molecular basis of this pathogen
82
. The availability of the genome-sequence will help 
better understand this organism. So there is a need for new antibacterial agents and 
protocols for treating these infections. 
The minimum inhibitory concentrations (MIC) of the 29 S,S`-heterosubstituted disulfides 
1-6 were evaluated against a live vaccine strain (LVS) of Francisella tulerensis (F.T) by 
broth dilution (Table 2.8).  
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Table (2.8) MIC’s of S,S’-heterosubstituted disulfides against Francisella tularensis. 
Substrate             Compound               R                       Francisella tularensis  
                               MIC (µg/mL)  
S,S`- dialkoxy substituted disulfides 
    1a  propyl    16  
    1b  isopropyl   4       
    1c  butyl    4 
    1d  s-butyl    16 
    1e  phenyl    1 
S,S`- dithio substituted disulfides 
    2a  propyl    1 
    2b  isopropyl   8 
    2c  butyl    4 
    2d  s-butyl    16 
    2e  phenyl    2 
S,S`- diamino substituted disulfides 
    3a  propyl    16 
    3b  isopropyl   2 
    3c  butyl    4 
    3d  s-butyl    8 
    3e  phenyl    0.5 
S,S`- diamino disubstituted disulfides 
    4a  methyl    8  
    4b  ethyl    16 
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    4c  isopropyl   32 
    4d  allyl    16 
    4e  isobutyl   1 
Chiral S,S’-heterosubstituted disulfides 
    5a  (S) - s-butyl   16 
    5b  (R) - s-butyl   16   
    5c  1-phenylpropyl  16  
    5d  2-phenylpropyl  8  
    5e  (D)-menthyl   4   
    5f  (L)-menthyl   4  
    5g  (+)-menthyl   4  
Chiral amines 
    6a  (R)-benzyl-(1-phenylethyl) 16  
    6b  (S)-benzyl-(1-phenylethyl) 16  
 
Control   Ciprofloxacin     0.125 
 
There was no obvious structure-activity relationship among these 29 analogues, but some 
of the compounds showed good activities with MIC’s as low as 0.5 µg/ml. Bis-
diaminophenyl disulfide (3e) was observed to be the most active compound.  
 
2.9 Anti-Bartonella activity: 
Similarly, a selection of disulfides were tested against various species of Bartonella, 
namely B. henselae (houston-1), B. quintana (U-mass), B. henselae Marseille and B. 
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henselae (SA-1) by disk diffusion assay. Rifampicin was used as a positive control along 
with DMSO, which was used to solubulize the compounds.  
Table (2.9) Zone of inhibition data of S,S’-heterosubstituted disulfides against Bartonella 
sp. 
Compound          B.henselae B. Quintana B. henselae B. henselae 
     Houston-1        U-mass  Marseille     SA-1 
     Zone of inhibition (mm) 
S,S`- dialkoxy substituted disulfides 
1a    0  0  0  0 
1b    12  25  12  11 
1c    0  0  0  0  
1d    0  0  0  0 
1e    0  0  0  0  
  
S,S`- dithio substituted disulfides 
2a    0  12  10  0  
2b    0  0  10  0 
2d    0  0  8  0 
2e    17  0  17  8 
 
Rifampin   62  53  22  68 
   
DMSO    0  0  0  0 
 
Surprisingly, most of the disulfides were completely inactive (Table 2.9). Only 
compound 1b, diisopropoxy disulfide, which was the most active compound against 
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Staphylococcus aureus, showed a small zone of inhibition. S,S’-heterosubstituted 
disulfides were also tested against Escherichia coli and were found to be inactive. MIC’s 
of all the disulfides were greater than 128 µg/ml.  
2.10 Anti-fungal activity 
Given that, previously, N-thiolated β-lactams were found to have antifungal properties
87
, 
we decided to examine the disulfides against Candida albicans, one of the most common 
human commensal organisms that lives in the mouth and gastrointestinal tract. It is 
present in about 80%
88
 of healthy individuals. Entry of these fungal cells in the blood 
stream causes candidiasis, infections which vary from superficial to systemic, and are 
often life threatening. Invasive candidiasis
89
 is very prevalent in intensive care units and 
is a major cause of mortality in 33-47% of immunocompromised individuals in hospitals. 
Reduced susceptibility of Candida species towards the commonly used antifungal agents 
has raised concerns over a need for effective antifungal agents.  
Fungal susceptibility testing of diisopropoxy disulfide (1b) against C. albicans was done, 
by Sonja Dickey in Dr. Daniel Lim’s lab in the USF Biology department, according to 
NCCLS document M27-A2 in Yeast Nitrogen Broth (YNB) using 1 µg/ml, 0.5 µg/ml, 
0.25 µg/ml, and 0.125 µg/ml concentrations of diisopropoxy disulfide (1b). Trypan blue 
was used for staining of non-viable cells. Two controls were used as well, a viable 
control using only C. albicans in YNB and a dead control using C. albicans in phosphate 
buffered saline (PBS) that was heat killed (boiled for 5 minutes). The MIC of 
diisopropoxy disulfide (1b) towards C. albicans was found to be 0.5 µg/ml. 
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2.10.1 Trypan Blue Staining: 
To further assess the antifungal activity of the most active disulfide compound, 
diisopropoxy disulfide (1b), a cell staining  assay was carried out by Sonja Dickey in Dr. 
Daniel Lim’s lab in the Department of Biology, University of South Florida,. This 
staining procedure is based on the observation that viable fungal cells do not take up the 
trypan blue dye while the non-viable cells do, and indicate cell viability in the presence of 
the drug. 
N
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Figure (2.21) Trypan Blue 
Trypan staining assay images (Figures 2.22 & 2.23) of C.albicans treated with 
diisopropoxy disulfide show that only the cells in the heat-killed control absorb the dye.  
None of the cells from the susceptibility test or the viable control from the yeast nutrient 
broth (YNB) stained blue, indicating that diisopropoxy disulfide is fungistatic and not 
fungicidal.  
 
  
Figure (2.22) Trypan Blue staining showing live fungal cells.
Figure (2.23) Trypan Blue staining of heat killed control showing dead fungal cells.
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2.11 Efforts towards prodrug/dual action drug synthesis  
The advent of multi-drug resistant microbes has made it very difficult to treat the diseases 
caused by them. A way to circumvent this would be by means of dual-action drug 
approach. In this approach two drugs with different modes of action are connected via a 
cleavable covalent linkage and introduced into the microbial cell. Upon entering the cell 
the linkage is broken enzymatically and releases both the drugs. These drugs target 
different biological pathways and so have a better chance to inhibit the microbe than in 
case of a drug with a single target. 
In our efforts to make disulfide-based dual-action antibiotics, we unsuccessfully tried to 
couple disulfide 1b with 4-(2-chlorophenyl)-3-methoxyazetidin-2-one, ciprofloxacin and 
penicillin G (Fig 2.24). All these reactions were tried varying the solvents 
(dichloromethane, benzene), bases (triethylamine, diisopropylamine and pyridine) and 
temperatures (0 – 50 °C). Ciprofloxacin and penicillin G were used from commercially 
available sources. 4-(2-chlorophenyl)-3-methoxyazetidin-2-one was synthesized 
according to the previously published protocol in Dr. Turos’ lab. 
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Figure (2.24) Attempted coupling reactions of diisopropoxy disulfide. 
 
Apart from these, the synthesis of disulfide linked ciprofloxacin and penicillin dimers 
prepared from sulfur monochloride were also attempted (Fig 2.25). These results also 
were not encouraging. The reactions did not yield any new products at ambient 
temperature and decomposed at elevated temperatures (50 °C). 
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Figure (2.25) Attempted synthesis of ciprofloxacin and penicillin disulfides. 
The only reaction that worked well was the synthesis of a t-butyl carbamate analog of 
ciprofloxacin. This ciprofloxacin prodrug exhibited potent activity, having an MIC < 
0.125 µg/ml against Staphylococcus aureus and MRSA, on par with ciprofloxacin. 
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N-Boc ciprofloxacin (7)  
Figure (2.26) Synthesis of N-Boc ciprofloxacin. 
 
2.12 Conclusions and future directions 
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S,S’-Heterosubstituted disulfides were synthesized in good yields from sulfur 
monochloride, and characterized by 
1
H NMR. Most of these compounds showed 
promising growth inhibition activities against Staphylococcus aureus and methicillin-
resistant Staphylococcus aureus. Diisopropoxy disulfide (1b) and bisdimethyldiamino 
disulfide (4a) were found to be the most potent among the set of compounds. The data 
from the Kirby-Bauer assay concluded that the activity diminished in presence of 
additives that contain a free sulfhydryl group. It is likely that this might be due to the 
cleavage of the S-heteroatom or disulfide bonds, and the formation of a biologically 
inactive mixed disulfide. As of yet, we have not been able to confirm this in solution, or 
to obtain isolable mixed disulfide adducts. From the bacterial viability assay these 
disulfides were found to be bacteriostatic in nature. These compounds have also shown 
decent activities against Francisella tulerensis, the lowest MIC was observed for 
diphenyl diamino disulfide (3e). 
O
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N
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1b - Best Staph inhibitor
(MIC 0.5    g/ml)
3e - Best Francisella inhibitor
(MIC 1    g/ml)µ µ  
Figure (2.27) Most active disulfide analogs 1b and 3e 
From the various antimicrobial tests and assays performed, S,S’-heterosubstituted 
disulfides were observed to be bacteriostatic inhibiting gram-positive bacteria such as 
Staphylococcus aureus and its multi-drug resistant variant.  
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The SEM images (Fig 2.20) of MRSA treated with bis-isopropoxy disulfide (1b) also 
showed similarity to those of N-thiolated β-lactams. Neither affects the integrity of the 
bacterial cell wall, nor alters cell morphology.  
These compounds were tested alongside N-thiolated β-lactams and aryl-alkyl disulfides 
synthesized previously in Dr. Turos’ lab and have shown comparable zones of inhibition 
against MRSA. In addition, it has been also shown that their bioactivity can be cancelled 
out in the presence of thiophilic additives, such as cysteine, glutathione and coenzyme A 
(Figures 2.14, 2.16 & 2.17).     
It can also be observed that the structural similarity in having a cleavable S-heteroatom 
bond in all the three mentioned antibacterials (a sulfur-nitrogen bond in N-thiolated β-
lactams, sulfur-sulfur bond in aryl-alkyl disulfides and three cleavable S-heteroatom 
bonds in S,S’-heterosubstituted disulfides) gives an understanding of the possible active 
component and consequently the similarity in the target moiety. 
It was established that N-thiolated β-lactams target coenzyme A and, subsequently the 
FabH
64
 enzyme regulating bacterial fatty acid pathway. It can now be hypothesized there 
might be a parallel in the mode of action between the N-thiolated β-lactams and the S,S’-
heterosubstituted disulfides. 
The next logical step would be to confirm the hypothesized mode of action of these 
compounds. With the aid of tools like proteomics, one can get an understanding as to 
which bacterial pathway, if any, is being inhibited by the drug. Proteomics is the branch 
of genetics that deals with the full set of proteins encoded by the genome. A basic 
experiment would include incubating the bacteria with a drug and analyzing the bacterial 
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contents for any over or under expressed proteins with the help of a mass spectrometer. 
This would specify the protein and in turn the pathway that is being affected by the drug. 
Apart from being antibacterials themselves, the presence of cleavable S-heteroatom 
bonds in their structure gives S,S’-heterosubstituted disulfides a potential to be modified 
as prodrugs or dual-action drugs. The prodrug nature facilitates the drug to be masked 
from the various bacterial metabolic enzymes and gives the drug extra time to show its 
inhibitory activity. This helps in lowering the dose of the drug that needs to be 
administered. The advantage with dual-action drugs is the presence of two antibacterial 
agents with different modes of action. Once these drugs enter the bacterial cell, they are 
prone to enzymatic cleavage and can simultaneously target different bacterial metabolic 
pathways. This can possibly be a means of overcoming bacterial resistance mechanisms. 
Due to the advent of so many different bacterial resistance mechanisms there is always a 
need for effective antimicrobial agents with novel modes of action. The present work 
shows S,S’-heterosubstituted disulfides as antimicrobial agents against various bacteria 
including Staphylococcus aureus, MRSA, Francisella tulerensis and the fungus Candida 
albicans. These structurally-simple disulfides may serve as new leads to the development 
of effective antibacterials for drug-resistant microbial infections. 
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CHAPTER THREE 
 
MATERIALS AND METHODS 
 
3.1 Antimicrobial Testing to Determine Minimum Inhibitory Concentration 
All the testing was performed according to NCCLS guidelines. [NCCLS (National 
Committee for Clinical Laboratory Standards) Methods for Dilution of Antimicrobial 
Susceptibility Tests for Bacteria that Grow Aerobically. NCCLS Document M7-A5, Vol. 
17, No. 2, 1997.] 
3.1.1 Inoculum Preparation 
10 ml of Mueller Hinton broth was added to a sterile test tube. Using a sterile cotton 
swab, the broth-containing test tube was inoculated with 3-5 colonies from the 
appropriate overnight culture. The test tube was placed in an incubator for approximately 
2 hours at 35 to 37°C, or until the culture reached an optical density of 0.08-0.10 at 625 
nm wavelength.  This is equal to 0.5 McFarland standard [1.5X10^8 CFU (colony 
forming units) /ml]. The culture as needed was adjusted to obtain the appropriate optical 
density. If the bacterial suspension is too turbid, it can be diluted with more diluent. If the 
suspension is not turbid enough, more bacteria can be added. Once the appropriate optical 
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density was obtained, a 1:1000 dilution of the above culture in a sterile media storage 
bottle was prepared.  
3.1.2 Preparation of Drug-Containing Mueller Hinton Agar in 24-well Plates 
Using a 1 mg/mL stock solution of the test drug in DMSO, the following volumes were 
added in each the 12 wells: 256 µl, 128 µl, 64 µl, 32 µl, 16 µl, 8 µl, 4 µl, 2 µl, 1 µl, 0.5 
µl, 0.25 µl, 0.125 µl, respectively. The following volume of molten Mueller Hinton Agar 
was then added into each of the 12 wells containing the above volume of test drug: 744 
µl, 872 µl, 936 µl, 968 µl, 984 µl, 992 µl, 996 µl, 998 µl, 999 µl, 999.50 µl, 999.75 µl, 
999.875 µl, respectively. Each well was mixed using a pipette and allowed the drug-
containing agar to solidify at room temperature before inoculation. This gives the 
following order of drug concentrations in the wells: 256 µg/ml, 128 µg/ml, 64 µg/ml, 32 
µg/ml, 16 µg/ml, 8 µg/ml, 4 µg/ml, 2 µg/ml, 1 µg/ml, 0.5 µg/ml, 0.25 µg/ml and 0.125 
µg/ml. 
3.1.3 Inoculation of Drug-Containing Mueller Hinton Agar 
Optimally, within 15 minutes after adjusting the turbidity of the inoculum suspension and 
preparing a 1000-fold dilution, 1 µl of the appropriate inoculum was added to each well 
of the 24-well plate, containing solidified agar/test drug. The plates were then placed into 
the incubator at 35 to 37 °C. 
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3.1.4 Reading the Plates and Interpreting the Results 
After 16 to 18 hours of incubation, each plate was examined for bacterial growth. The 
drug concentration in the well showing no visible bacterial growth as detected with the 
unaided eye is considered the MIC value. These values are recorded in table 3.1. 
3.2 Kirby-Bauer Diffusion Assay 
3.2.1 Culture preparation 
 From a freezer stock in tryptic soy broth (Difco Laboratories, Detroit, MI) and 20 % 
glycerol, a culture of each microorganism was transferred with a sterile Dacron swab to 
Trypticase® Soy Agar (TSA) plates (Becton Dickinson Laboratories, Cockeysville, MD), 
streaked for isolation, and incubated at 37 °C for 24 h. A 10
8
 standardized cell count 
suspension was then made in sterile phosphate buffered saline (pH 7.2) and swabbed 
across fresh TSA plates. 
3.2.2 Testing procedure 
Sterile saline (5 mL) was inoculated with a swab of bacteria with a sterile cotton plug. 
The concentration was then adjusted to 0.5 McFarland standard as explained earlier. This 
bacterial solution was then streaked across a TSA plate to a give an even lawn of 
bacteria. Sterile pipet tips were used to drill 6 mm wells into the agar plate, then 20 µL of 
1 mg/mL drug in DMSO was added to the well. Plates were incubated overnight at 37 °C. 
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3.3 Anti-Francisella testing: 
All 29 disulfides were tested against a live vaccine strain (LVS) of Francisella tularensis 
by the broth dilution technique as described below. This was carried out in a biosafety 
level 3 facility by John Thomas in Dr. Burt Anderson’s laboratory at USF College of 
Medicine. 
3.3.1 Culture preparation 
In a 50 ml conical tube, 320 µg of the test disulfide was added to 10 ml of Mueller-
Hinton (MH) broth at room temperature to give a concentration of 32 µg/ml. 5 mL of this 
broth was added and mixed into another conical tube containing 5 mL of MH broth to 
afford a final disulfide concentration of 16 µg/ml. These steps were repeated to obtain 
various concentrations. A 5 mL aliquot was removed from the final tube having a 
disulfide concentration of 0.25µg/mL.  
3.3.2 Addition of LVS  
Two full cotton swabs worth of LVS growth culture was suspended into 10 mL of MH 
broth at room temperature. From this stock, 25 µl was added into each of the dilution 
tubes prepared above. These tubes were incubated at 36 °C in an incubator with 0% CO2.  
3.3.3 Controls 
Three control tubes were also prepared, containing the following: 
1. 25 µl LVS in 5 mL of MH broth in a 50 mL conical tube.  
2. 25 µl LVS in 5 mL of MH broth in a 50 mL conical tube with dilutions of DMSO 
added that match those of the above drug dilutions.  
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3. 5 mL of MH broth in a 50 mL conical tube. 
After 48 hours of incubation, all of the tubes were examined visually to define the 
concentration of disulfide that inhibits LVS growth. These values are recorded in table 
3.1. 
Table 3.1 Antimicrobial activities of S,S’-heterosubstituted disulfides 1-6. 
                                                                                     Minimum Inhibitory Concentration         
                                                                                                      (µg/mL)                       
Disulfide             Compound          alkyl                                  F.T S.A MRSA  
          number  R 
(RO-S)2   
   1a  propyl    16 32 32 
   1b  isopropyl   4       1 0.5 
   1c  butyl    4 0.25 8 
   1d  s-butyl    16 16 8 
   1e  phenyl    1 2 2 
(RS-S)2  
   2a  propyl    1 32 32 
   2b  isopropyl   8 32 32 
   2c  butyl    4 64 32 
   2d  s-butyl    16 32 64 
   2e  phenyl    2 8 8 
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(RONH-S)2 
   3a  propyl    16 8 4 
   3b  isopropyl   2 32 32 
   3c  butyl    4 8 32 
   3d  s-butyl    8 16 16 
   3e  phenyl    0.5 4 4 
(R2N-S)2 
   4a  methyl    8 0.25 0.5  
   4b  ethyl    16 2 2 
   4c  isopropyl   32 2 1 
   4d  allyl    16 1 0.5 
   4e  isobutyl   1 16 16 
(R*O-S)2 
   5a  (S) - s-butyl   16 16 32 
   5b  (R) - s-butyl   16 16 32 
   5c  1-phenylpropyl  16 16 32 
   5d  2-phenylpropyl  8 16 16 
   5e  (D)-menthyl   4 8 8  
   5f  (L)-menthyl   4 8 16 
   5g  (+)-menthyl   4 8 16 
(R*R*N-S)2 
   6a  (R)-benzyl-(1-phenylethyl) 16 16 64 
   6b  (S)-benzyl-(1-phenylethyl) 16 16 64 
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Control   
                                   Ciprofloxacin     0.125 
   Penicillin-G      0.125 16 
F.T: Francisella tularensis (Live Vaccine Strain) 
S.A: Staphylococcus aureus (ATCC-25923) 
MRSA: Methicillin-resistant Staphylococcus aureus (ATCC-43300) 
 
3.4 In vitro Anti-Bartonella activity by disk diffusion method 
B.henselae (hoston-1), B.quintana (U-mass), B.henselae Marseille and B.henselae (SA-1) 
were inoculated onto chocolate agar plates to create a confluent lawn of growth.  A 6 mm 
diameter paper disk was then placed in the center of the plate before incubation. Plates 
were incubated at 37 °C for one week and the diameter of growth inhibition was then 
measured and recorded. 
3.4.1 Preparation of antibiotic-containing paper disks 
The preparation of disks was done in an identical fashion each time, as it is important to 
standardize the procedure as much as possible. All antibiotics were predissolved in 
DMSO to a final concentration of 1 mg/ml, and added to the paper disks as a 1 mg/ml 
solution using a volume of 20 µl.  This volume readily adsorbed into the paper disks 
quickly, and gave a total standard amount of 20 µg of antibiotic per disk. To load the 
antibiotics, 6 mm paper disks were placed on a sheet of aluminum foil in the biological 
safety cabinet (BSC).  Disks can be easily handled without damage using fine-point 
forceps. To each disk was added 20 µl of antibiotic solution at a concentration of 1 mg/ml 
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dissolved in DMSO. A negative control consisting of 20 µl DMSO/disk and a positive 
control consisting of 20 µl of rifampicin at 0.1mg/ml in DMSO were also prepared. Each 
disk contained 20 µg of the antibiotic being tested while the positive control disk 
contained 2.0 µg of rifampicin. The disks were allowed to dry in the BSC for at least 20 
minutes, then placed by forceps in a sealable bag with desiccant and stored sealed in the 
refrigerator. 
3.4.2 Inoculation of agar plates for disk diffusion testing 
Bacteria from 4-5 day old plates was harvested and resuspended in 1.0 ml sterile HIB. 
Turbidity was adjusted to about McFarland 2.0 by inspection. The suspension was spread 
over the surface of a labeled chocolate agar plate using a swab and allowed to dry into the 
agar in the BSC for 10-15 minutes. Forceps were used to place the disk in the center of 
the plate. The disk was tapped gently to make sure it adhered to the plate. The plates were 
then inverted and kept at 35 °C in a CO2 incubator for one week. The zones of inhibition 
were then measured and recorded to the nearest mm for each plate. 
3.5 Fungal viability assay 
Diisopropoxy disulfide was tested for fungal viability by a Trypan Blue staining protocol. 
50 µl of a Candida albicans culture and 50 µl of a 0.4% Trypan Blue solution in water 
(w/v) were mixed in a 2 ml plastic microcentrifuge tube. After 5 minutes, 20 µl of the 
mix was loaded into a disposable cell-counting chamber (Cellometer (Registered), 
Nexcelom Bioscience, Lawrence, MA) and viewed microscopically (Olympus BX60, 
Olympus, Center Valley, PA) at 40X magnification.  Pictures were taken using a Spot 
Flex Camera (Diagnostic Instruments, Inc., Sterling Heights, MI).  
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3.6 Cytotoxicity testing 
 
Primary bovine primary aortic endothelial cells and EBM-2  (endothelial basal medium) 
cell culture medium were from Lonza Walkersville, Inc. Cells were maintained in culture 
medium supplemented with 10% FBS (fetal bovine serum) and 100 IU penicillin/100 
µg/ml streptomycin sulfate in a humidified incubator containing 5% CO2 at 37 
o
C. For 
cytotoxicity testing, cells were trypsinized, counted, centrifuged at 120 x g, and 
resuspended in fresh culture medium. Cells were plated in a volume of 100 µl (2.5 x 10
4
 
cells/well) in 96-well flat-bottom culture dishes. After 16-18 h of incubation, 100 µl of 
medium or medium containing test samples was added to each well. Tests were 
performed in triplicate. After 48 h, 20 µl of MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) (1.25 - 4 mg/ml in DPBS) was added to each well, and the 
cells were further incubated for 2 - 3.5 h. The medium was aspirated, and the formazan 
product generated in each well was dissolved in 100 µl DMSO. Plates were read in a 
BioTek Synergy 2 SLFA plate reader set at 540 nm (background subtract at 660 nm). 
Cell viability was calculated as percent of control (sample absorbance/control medium 
absorbance x 100). 
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Table 3.2 Cytotoxicity data of diisopropoxy disulfide (1b) 
Sample Concentration 
 (µg/ml) 
Mean Std. 
Deviation 
% control 
Absorbance 
Appearance 
after 48hr 
1b 0.3125 0.248 0.006 90.6 ok 
1b 1.25 0.271 0.017 98.9 ok 
1b 5 0.299 0.021 109.4 ok 
1b 20 0.252 0.010 92.0 ok 
 
Diisopropoxy disulfide was checked for cytotoxicity by MTT assay as explained above. 
It was observed that this compound did not show any cytotoxic activity against bovine 
aortic endothelial cells upto the concentration of 20 µg/ml. 
3.7 Synthetic procedures 
All the chemicals used for the synthesis of the disulfide compounds were purchased from 
Aldrich Chemical Company and used without further purification. Sulfur monochloride 
was purified by distilling from sulfur and charcoal (100:4:1 S2Cl2/sulfur/charcoal) 
(Fieser, L. F.; Fieser, M. Reagents for Organic Synthesis; John Wiley and Sons: New 
York, 1967; Vol. 1). Thin layer chromatography was performed using Silica Gel 60 F254 
purchased from EMD Chemicals. A UVG-11 Minera light lamp was used to visualize the 
TLC plates. The NMR spectra were recorded in deuterated chloroform on a Bruker 250 
MHz instrument. High performance liquid chromatography (HPLC) was done on a 
Shimadzu Prominence system using a reverse-phase Shimadzu column (C18, 0.46×5 
cm). Samples were eluted using a gradient from 100% of a 10 mM PBS solution (pH 7.4) 
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to 100% of acetonitrile in 22 min at a flow rate of 1 ml/min. The detection was performed 
using a Shimadzu SPD-20A UV–visible detector at 254 nm. 
3.7.1 General procedure for the synthesis of S,S’-heterosubstituted disulfide 1-6. 
To a stirred solution of equimolar concentrations (1 mmol) of the selected alcohol, amine, 
or thiol and triethylamine in dry dichloromethane at -20 
°
C was added dropwise a 
solution of sulfur monochloride (0.5 mmol) in dichloromethane. The reaction was 
brought to room temperature after the addition was completed and stirring was continued 
for about 1 hr. The reaction was worked up by the addition of about 100 mL of ice-cold 
water. This was stirred for a few minutes, transferred to a separatory funnel, and the 
aqueous phase was removed by draining the organic layer. The organic layer was further 
washed twice with 50 mL of ice-cold water to remove the triethylamine hydrochloride, 
and washed with 50 mL of brine to dry the organic layer. The dichloromethane layer was 
further dried by the addition of anhydrous magnesium sulfate, filtered and concentrated 
in vacuo. The product obtained was purified by silica gel chromatography and 
characterized by 
1
H NMR. Due to the absence of any ionizable functionalities in the S,S’-
heterosubstituted disulfides, mass spectroscopy was not helpful because no parent ion 
could be identified for any of the compounds. 
Synthesis of S,S’-dipropoxy disulfide (1a) 
To a stirred solution of n-propanol (5 mL, 1mmol) and triethylamine (9.36 mL, 1 mmol) 
in 20 mL of anhydrous dichloromethane at -20 
°
C was added dropwise a solution of 
sulfur monochloride (2.68 mL, 0.5mmol) in 10 mL of dichloromethane. The reaction was 
brought to room temperature after the addition was completed and stirring was continued 
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for about 1 hr. The reaction was worked up as described in the general procedure. All the 
yields mentioned below are after column chromatography. 
1a: Isolated 77.3 mg (85%) as a colorless oil;
 1
H NMR (250 MHz, CDCl3): δ 3.38-3.43 (t, 
2H, J= 6.8 Hz), 1.82-1.96 (m, 2H), 1.01-1.07 (t, 3H, J= 7.3 Hz). 
1b: Isolated 79.2 mg (87%) as a colorless oil; 
1
H NMR (250 MHz, CDCl3): δ 3.95-4.15 
(m, 1H), 1.24-1.32 (m, 6H). 
1c: Isolated 87.2 mg (83%) as a colorless oil; 
1
H NMR (250 MHz, CDCl3): δ 3.4-3.46 (t, 
2H, J= 6.8 Hz), 1.8-1.91 (m, 2H), 1.4-1.55 (m, 2H), 0.91-0.97 (t, 3H, J= 7.4 Hz). 
1d: Isolated 85 mg (81%) as a colorless oil; 
1
H NMR (250 MHz, CDCl3): δ 3.67-3.93 (m, 
1H), 1.38-1.68 (m, 2H), 1.08-1.28 (d, 3H, J = 7.5 Hz), 0.75-0.96 (t, 3H, J = 6.3 Hz). 
1e: Isolated 95 mg (76%) as a dark green oil 
1
H NMR (250 MHz, CDCl3): δ 7.27-7.40 
(m, 5H). 
2a: Isolated 92.1 mg (86%) as a yellow oil; 
1
H NMR (250 MHz, CDCl3): δ 2.91-2.97 (t, 
2H, J= 7.1 Hz), 1.73-1.76 (m, 2H), 1-1.06 (t, 3H, J= 7.3 Hz). 
2b: Isolated 90.2 mg (85%) as a yellow oil; 
1
H NMR (250 MHz, CDCl3): δ 3.19-3.37 (m, 
1H), 1.38-1.41 (d, 6H, J= 6.8 Hz). 
2c: Isolated 108.9 mg (90%) as a yellow oil; 
1
H NMR (250 MHz, CDCl3): δ 2.68-3.01 
(m, 2H), 1.71-1.80 (m, 2H), 1.41-1.51 (m, 2H), 0.92-0.99 (t, 3H, J= 7.7 Hz). 
2d: Isolated 100.44 mg (83%) as a yellow oil; 
1
H NMR (250 MHz, CDCl3): δ 2.95-3.12 
(m, 1H), 1.58-1.83 (m, 2H), 1.36-1.41 (d, 3H, J= 6.2 Hz), 0.97-1.05 (t, 3H, J= 7.4 Hz). 
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 2e: Isolated 90.2 mg (85%) as pale yellow crystals; mp 31-33 °C; 
1
H NMR (250 MHz, 
CDCl3): δ 7.51-7.55 (m, 2H), 7.25-7.37 (m, 3H). 
3a: Isolated 58.5 mg (65%) as a reddish oil; 
1
H NMR (250 MHz, CDCl3): δ 3.11-3.17 (t, 
2H, J= 7.9 Hz), 1.55-1.65 (m, 2H), 1.46-1.52 (bs, 1H), 0.84-0.89 (t, 3H, J= 7.3 Hz). 
3b: Isolated 58.5 mg (65%) as a reddish oil;
 1
H NMR (250 MHz, CDCl3): δ 3.79-3.95 (m, 
1H), 1.28-1.3 (d, 6H, J= 6.5 Hz). 
3c: Isolated 62.43 mg (60%) as a reddish oil;
 1
H NMR (250 MHz, CDCl3): δ 3.63-3.71 
(m, 2H), 1.8-1.89 (m, 2H), 1.34-1.48 (m, 2H), 0.93-0.99 (t, 3H, J= 7.3 Hz). 
3d: Isolated 65.5 mg (63%) as a reddish oil; 
1
H NMR (250 MHz, CDCl3): δ 2.95-3.12 (m, 
1H), 1.58-1.83 (m, 2H), 1.36-1.41 (m, 3H), 0.97-1.05 (m, 3H). 
3e: Isolated 80.6 mg (65%) as a reddish oil; 
1
H NMR (250 MHz, CDCl3): δ 7.14-7.27 (m, 
2H), 6.68-6.81 (m, 3H), 3.65 (bs, 1H). 
4a: Isolated 55.5 mg (73%) as a colorless oil; 
1
H NMR (250 MHz, CDCl3): δ 2.52 (s, 
3H). 
4b: Isolated 78.1 mg (75%) as a colorless oil; 
1
H NMR (250 MHz, CDCl3): δ 3.40-3.48 
(q, 2H, J= 7.4 Hz), 1.65-1.71 (t, 3H, J= 7.3 Hz). 
4c: Isolated 99.1 mg (75%) as a colorless oil; 
1
H NMR (250 MHz, CDCl3): δ 4.05-4.15 
(m, 1H), 1.27-1.33 (t, 6H, J= 7 Hz). 
4d: Isolated 89.6 mg (70%) as a colorless oil; 
1
H NMR (250 MHz, CDCl3): δ 5.73-5.9 
(m, 4H), 5.07-5.16 (m, 8H), 3.34-3.37 (d, 8H, J= 6.3 Hz). 
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4e: Isolated 113.6 mg (71%) as a colorless oil; 
1
H NMR (250 MHz, CDCl3): δ 2.64-2.7 
(bs, 1H), 2.42-2.45 (d, 1H, J= 7.1 Hz), 1.93-2.13 (m, 1H), 0.89-0.92 (d, 6H, J= 6.6 Hz). 
5a: Isolated 81.9 mg (78%) as a colorless oil; [α]
25
D –10.1° (c 0.29, CH2Cl2); 
1
H NMR 
(250 MHz, CDCl3): δ 3.85-3.91 (m, 1H), 1.53-1.69 (m, 2H), 1.26-1.31 (m, 3H), 0.91-0.97 
(m, 3H). 
5b: Isolated 79.8 mg (76%) as a colorless oil; [α]
25
D +9.2° (c 0.25, CH2Cl2);  
1
H NMR 
(250 MHz, CDCl3): δ 3.86-3.91 (m, 1H), 1.55-1.67 (m, 2H), 1.26-1.31 (m, 3H), 0.91-0.97 
(m, 3H). 
5c: Isolated 58.45 mg (70%) as a colorless oil; 
1
H NMR (250 MHz, CDCl3): δ 7.28-7.39 
(m, 5H), 4.59-4.65 (m, 1H), 1.77-1.87 (m, 2H), 0.92-0.98 (t, 3H, J= 7.4 Hz). 
5d: Isolated 60.95 mg (73%) as a colorless oil; 
1
H NMR (250 MHz, CDCl3): δ 7.03-7.18 
(m, 5H), 3.50-3.53 (d, 2H, J= 6.8 Hz), 2.69-2.83 (m, 1H), 1.07-1.1 (d, 3H, J= 6.7 Hz). 
3.7.2 Synthesis of S,S’-heterosubstituted disulfides of menthol:  
To an ice-cooled suspension of sodium hydride (oil removed from hexanes) (1.5 mmol) 
in anhydrous tetrahydrofuran (THF), a solution of menthol (1 mmol) in THF was added 
dropwise and was stirred until the evolution of hydrogen stopped. This was followed by 
the addition of a solution of sulfur monochloride (0.5 mmol) in THF dropwise under 
argon atmosphere. The reaction was stirred until all the starting material was consumed, 
monitoring by TLC. The reaction mixture was then concentrated in vacuo and purified by 
silica gel chromatography. 
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5e: Isolated 56.1 mg (60%) as a colorless oil; [α]
25
D +32.1° (c 0.35, CH2Cl2); 
1
H NMR 
(250 MHz, CDCl3): δ 3.38-3.46 (m, 1H), 2.15-2.21 (m, 1H), 1.95-2 (m, 1H), 1.59-1.70 
(m, 2H), 1.42-1.45 (m, 1H), 1.25-1.27 (m, 1H),  0.98-1.17 (m, 3H), 0.91-0.95 (m, 6H), 
0.81-0.84 (m, 3H).  
5f: Isolated 58 mg (62%) as a colorless oil; [α]
25
D –28.7° (c 0.15, CH2Cl2); 
1
H NMR (250 
MHz, CDCl3): δ 3.37-3.47 (m, 1H), 2.15-2.21 (m, 1H), 1.93-2 (m, 1H), 1.59-1.70 (m, 
2H), 1.26-1.39 (m, 3H), 1.01-1.13 (m, 2H), 0.94-0.95 (m, 3H), 0.91-0.93 (m, 3H), 0.81-
0.84 (m, 3H). 
5g: Isolated 60.7 mg (65%) as a colorless oil; 
1
H NMR (250 MHz, CDCl3): δ 3.37-3.47 
(m, 1H), 2.15-2.21 (m, 1H), 1.93-2 (m, 1H), 1.59-1.70 (m, 2H), 1.26-1.39 (m, 3H), 1.01-
1.13 (m, 2H), 0.94 (d, 3H, J= 4.3 Hz), 0.92 (d, 3H, J= 3.8 Hz), 0.81-0.84 (d, 3H, J= 6.8 
Hz). 
The compounds 6a and 6b were synthesized according to the general procedure 
explained in section 3.6.1. 
6a: Isolated 67.7 mg (56%) as a colorless oil; [α]
25
D +23° (c 0.59, CH2Cl2); 
1
H NMR (250 
MHz, CDCl3): δ 7.13-7.29 (m, 10H), 3.86-3.88 (m, 3H), 1.42-1.46 (m, 3H). 
6b: Isolated 70.2 mg (58%) as a colorless oil; [α]
25
D –25° (c 0.45, CH2Cl2); 
1
H NMR (250 
MHz, CDCl3): δ 7.17-7.27 (m, 10H), 3.82-4.3 (m, 3H), 1.44 (d, 3H, J= 6.6 Hz). 
 
3.7.3 Synthesis of 7-(4-tert-Butoxycarbonyl-piperazin-1-yl)-1-cyclopropyl-6-fluoro-4-
oxo-1,4-dihydro-quinoline-3-carboxylic acid:  To a stirred solution of ciprofloxacin (390 
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mg, 1.0 mmol) and 1M sodium hydroxide solution (3 ml, 2.5 mmol) in 20mL of 
tetrahydrfuran was added di-tert-butyl dicarbonate (0.20 ml, 1.1 mmol). The reaction was 
stirred until all the starting material was consumed by monitoring with TLC. The reaction 
mixture was then concentrated in vacuo and purified by silica gel chromatography to give 
339.4 mg (67%) of the title compound as a white solid. 
1
H NMR (250 MHz, CDCl3): 
14.95 (bs, 1H), 8.79 (s, 1H), 8.06 (d, 1H, J= 13.0 Hz), 7.36-7.39 (d, 1H, J= 7.3 Hz), 
3.66-3.70 (m, 4H), 3.50-3.60 (m, 1H), 3.25-3.35 (m, 4H), 1.51 (s, 9H), 1.40-1.43 (m, 
2H), 1.20-1.23 (m, 2H). 
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CHAPTER FOUR 
 
SPECTRA 
 
 
Spectrum 4.1: 
1
H NMR (250 MHz, CDCl3) of compound 1a: 
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Spectrum 4.2: 
1
H NMR (250 MHz, CDCl3) of compound 1c:
ADS.008.esp
10 9 8 7 6 5 4 3 2 1 0
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
N
o
rm
a
liz
e
d
 I
n
te
n
s
it
y
3.202.362.032.00
7
.2
7
3
.4
6
3
.4
3
3
.4
0
1
.9
1
1
.8
8 1
.8
5
1
.8
2
1
.8
0
1
.4
9
1
.4
6
1
.4
3
1
.4
0
0
.9
7
0
.9
4
0
.9
1
O
S S
O
CH3
CH3
 
 
Spectrum 4.3: 
1
H NMR (250 MHz, CDCl3) of compound 1d: 
PR_sBuDS.esp
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Spectrum 4.4: 
1
H NMR (250 MHz, CDCl3) of compound 1b: 
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Spectrum 4.5: 
1
H NMR (250 MHz, CDCl3) of compound 1e:
 
ADS.010.esp
10 9 8 7 6 5 4 3 2 1 0
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
N
o
rm
a
liz
e
d
 I
n
te
n
s
it
y
5.00
7
.4
0
7
.3
7
7
.3
6
7
.3
3
7
.3
0
7
.2
9
7
.2
7
O
S
S
O
  
95 
 
 Spectrum 4.6: 
1
H NMR (250 MHz, CDCl3) of compound 2b: 
spec.009.esp
10 9 8 7 6 5 4 3 2 1 0
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
N
o
rm
a
liz
e
d
 I
n
te
n
s
it
y
6.001.08
7
.2
7
3
.3
7
3
.3
7 3
.3
4
3
.3
1
3
.2
9
3
.2
4
3
.2
2
3
.1
9
1
.4
1
1
.3
8
S S
S
S
CH3
CH3
CH3
CH3
Spectrum 4.7: 
1
H NMR (250 MHz, CDCl3) of compound 2c: 
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Spectrum 4.8: 
1
H NMR (250 MHz, CDCl3) of compound 2e: 
spec.011.esp
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Spectrum 4.9: 
1
H NMR (250 MHz, CDCl3) of compound 2d: 
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Spectrum 4.10: 
1
H NMR (250 MHz, CDCl3) of compound 2a: 
spec.004.esp
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Spectrum 4.11: 
1
H NMR (250 MHz, CDCl3) of compound 3b: 
AmDS.003.esp
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Spectrum 4.12: 
1
H NMR (250 MHz, CDCl3) of compound 3d: 
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Spectrum 4.13: 
1
H NMR (250 MHz, CDCl3) of compound 3e: 
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Spectrum 4.14: 
1
H NMR (250 MHz, CDCl3) of compound 3a: 
AmDS.013.esp
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Spectrum 4.15: 
1
H NMR (250 MHz, CDCl3) of compound 4e: 
AmDS.007.esp
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Spectrum 4.16: 
1
H NMR (250 MHz, CDCl3) of compound 4a: 
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Spectrum 4.17: 
1
H NMR (250 MHz, CDCl3) of compound 4c: 
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Spectrum 4.18: 
1
H NMR (250 MHz, CDCl3) of compound 4b: 
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Spectrum 4.19: 
1
H NMR (250 MHz, CDCl3) of compound 4d: 
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Spectrum 4.20: 
1
H NMR (250 MHz, CDCl3) of compound 5c: 
spec.130.esp
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Spectrum 4.21: 
1
H NMR (250 MHz, CDCl3) of compound 5g:
spec.140.esp
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Spectrum 4.22: 
1
H NMR (250 MHz, CDCl3) of compound 5d: 
spec.150.esp
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Spectrum 4.23: 
1
H NMR (250 MHz, CDCl3) of compound 6b: 
6a.esp
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Spectrum 4.24: 
1
H NMR (250 MHz, CDCl3) of compound 6a: 
3_29_0ld.esp
16 14 12 10 8 6 4 2 0 -2 -4
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
N
o
rm
a
liz
e
d
 I
n
te
n
s
it
y
3.383.2210.00
7
.2
7
7
.2
6
7
.2
0
7
.1
7
3
.9
0
3
.8
7 3
.8
6
3
.8
2
1
.4
5
1
.4
2
N
S
N
S
 
Spectrum 4.25: 
1
H NMR (250 MHz, CDCl3) of compound 5a: 
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 Spectrum 4.26: 
1
H NMR (250 MHz, CDCl3) of compound 5e: 
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Spectrum 4.27: 
1
H NMR (250 MHz, CDCl3) of compound 5b: 
 
PR_(-)_sBuDS.esp
10 9 8 7 6 5 4 3 2 1 0
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
N
o
rm
a
liz
e
d
 I
n
te
n
s
it
y
3.363.302.250.99
7
.2
7
3
.9
1
3
.8
9
3
.8
8
3
.8
6
1
.6
7
1
.6
4
1
.6
1
1
.5
8 1
.5
5
1
.3
1
1
.2
8
1
.2
8
1
.2
6
0
.9
7
0
.9
6
0
.9
4
0
.9
3
0
.9
2
0
.9
1
CH3
CH3
OS
SO
CH3
CH3
 
  
106 
 
Spectrum 4.28: 
1
H NMR (250 MHz, CDCl3) of compound 5f: 
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Spectrum 4.29: 
1
H NMR (250 MHz, CDCl3) of compound 7: 
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Spectrum 4.30: HPLC trace of (1b) and CoA after 30 min in phosphate buffer solution: 
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Spectrum 4.31: HPLC trace of 1b and CoA after 24 hrs in phosphate buffer solution: 
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Spectrum 4.32: HPLC trace of CoA in phosphate buffer solution: 
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